  [
    {
      "to": 1,
      "from": "Astrazeneca",
      "partnership": "Acquisition",
      "sector": "Drug discovery and Development",
      "modality": "Cell therapy",
      "companyName": "Gracell Biotechnologies",
      "marketValue": 1200
    },
    {
      "to": 2,
      "from": "Astrazeneca",
      "partnership": "Partnership",
      "sector": "Drug discovery and Development",
      "modality": "Vaccines",
      "companyName": "Omniose",
      "marketValue": "NA"
    },
    {
      "to": 3,
      "from": "Astrazeneca",
      "partnership": "Acquisition",
      "sector": "Drug discovery and Development",
      "modality": "Vaccines",
      "companyName": "Icosavax, Inc.",
      "marketValue": 1100
    },
    {
      "to": 4,
      "from": "Astrazeneca",
      "partnership": "Acquisition",
      "sector": "Drug discovery and Development",
      "modality": "Small molecule therapy",
      "companyName": "CinCor Pharma, Inc",
      "marketValue": 1800
    },
    {
      "to": 5,
      "from": "Astrazeneca",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "In-silico drug discovery",
      "companyName": "Absci",
      "marketValue": 247
    },
    {
      "to": 6,
      "from": "Astrazeneca",
      "partnership": "Acquisition",
      "sector": "Drug discovery and Development",
      "modality": "Cell therapy",
      "companyName": "Neogene Therapeutics",
      "marketValue": 320
    },
    {
      "to": 7,
      "from": "Astrazeneca",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Gene editing technology (TALEN based)",
      "companyName": "Cellectis",
      "marketValue": 245
    },
    {
      "to": 8,
      "from": "Astrazeneca",
      "partnership": "Partnership",
      "sector": "Biotechnology",
      "modality": "Minimal residual disease (MRD) testing",
      "companyName": "C2i Genomics",
      "marketValue": "NA"
    },
    {
      "to": 9,
      "from": "Astrazeneca",
      "partnership": "Partnership",
      "sector": "Biotechnology",
      "modality": "AI-powered diagnostics",
      "companyName": "Ibex Medical Analytics ",
      "marketValue": "NA"
    },
    {
      "to": 10,
      "from": "Astrazeneca",
      "partnership": "Partnership",
      "sector": "Healthcare SaaS",
      "modality": "Digital health tool",
      "companyName": "Hospital Bellvitge",
      "marketValue": "NA"
    },
    {
      "to": 11,
      "from": "Astrazeneca",
      "partnership": "Investment",
      "sector": "Biotechnology",
      "modality": "In-silico drug discovery",
      "companyName": "Verge Genomics",
      "marketValue": 882
    },
    {
      "to": 12,
      "from": "Astrazeneca",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Cell therapy",
      "companyName": "QuellTX",
      "marketValue": 2085
    },
    {
      "to": 13,
      "from": "Astrazeneca",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Antibody-Drug Conjugate (ADC)",
      "companyName": "LaNova Medicines",
      "marketValue": 600
    },
    {
      "to": 14,
      "from": "Astrazeneca",
      "partnership": "Partnership",
      "sector": "Drug discovery and Development",
      "modality": "Small molecule therapy",
      "companyName": "Ascentage Pharma",
      "marketValue": "NA"
    },
    {
      "to": 15,
      "from": "Astrazeneca",
      "partnership": "Partnership",
      "sector": "Biotechnology",
      "modality": " Implantable medical device",
      "companyName": "Sernova Corp",
      "marketValue": "NA"
    },
    {
      "to": 16,
      "from": "Astrazeneca",
      "partnership": "Partnership",
      "sector": "Biotechnology",
      "modality": "Minimal residual disease (MRD) testing",
      "companyName": "Personalis, Inc.",
      "marketValue": "NA"
    },
    {
      "to": 17,
      "from": "Astrazeneca",
      "partnership": "Investment",
      "sector": "Biotechnology",
      "modality": "Protein degradation technology",
      "companyName": "Cullgen Inc",
      "marketValue": 35
    },
    {
      "to": 18,
      "from": "Astrazeneca",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Gene editing technology (Pin-point based)",
      "companyName": "Revvity",
      "marketValue": "NA"
    },
    {
      "to": 19,
      "from": "Astrazeneca",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Small molecule therapy",
      "companyName": "Eccogene ",
      "marketValue": 1985
    },
    {
      "to": 20,
      "from": "Astrazeneca",
      "partnership": "Partnership",
      "sector": "Drug discovery and Development",
      "modality": "Precision Therapeutics ",
      "companyName": "Cholesgen ",
      "marketValue": "NA"
    },
    {
      "to": 21,
      "from": "Astrazeneca",
      "partnership": "Partnership",
      "sector": "Disease Diagnostics and Devices",
      "modality": "AI-powered diagnostics",
      "companyName": "Qure.ai",
      "marketValue": "NA"
    },
    {
      "to": 22,
      "from": "Astrazeneca",
      "partnership": "Partnership",
      "sector": "Drug Delivery Technology",
      "modality": "Neuroscience Therapy",
      "companyName": "JCR Pharmaceuticals Co., Ltd.",
      "marketValue": "NA"
    },
    {
      "to": 23,
      "from": "Astrazeneca",
      "partnership": "Partnership",
      "sector": "Drug Delivery Technology",
      "modality": " Implantable medical device",
      "companyName": "Biora Therapeutics, Inc",
      "marketValue": "NA"
    },
    {
      "to": 24,
      "from": "Astrazeneca",
      "partnership": "Investment",
      "sector": "Drug manufacturing",
      "modality": "Cell therapy",
      "companyName": "AbelZeta Pharma",
      "marketValue": "NA"
    },
    {
      "to": 25,
      "from": "Astrazeneca",
      "partnership": "Acquisition",
      "sector": "Drug discovery and Development",
      "modality": "Cell therapy",
      "companyName": "TeneoTwo, Inc.",
      "marketValue": 100
    },
    {
      "to": 26,
      "from": "Astrazeneca",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Precision Therapeutics ",
      "companyName": "Neurimmune",
      "marketValue": 760
    },
    {
      "to": 27,
      "from": "Astrazeneca",
      "partnership": "Partnership",
      "sector": "Biotechnology",
      "modality": "In-silico drug discovery",
      "companyName": "Illumina Inc",
      "marketValue": "NA"
    },
    {
      "to": 28,
      "from": "Astrazeneca",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Precision Therapeutics ",
      "companyName": "RQ Biotechnology Ltd ",
      "marketValue": "NA"
    },
    {
      "to": 29,
      "from": "Astrazeneca",
      "partnership": "Acquisition",
      "sector": "Biotechnology",
      "modality": "Gene therapy",
      "companyName": "LogicBio Therapeutics, Inc.",
      "marketValue": 68
    },
    {
      "to": 30,
      "from": "Astrazeneca",
      "partnership": "Partnership",
      "sector": "Biotechnology",
      "modality": "Digital health tool",
      "companyName": "docdok.health",
      "marketValue": "NA"
    },
    {
      "to": 31,
      "from": "Astrazeneca",
      "partnership": "Investment",
      "sector": "Biotechnology",
      "modality": "Small molecule therapy",
      "companyName": "Rgenta Therapeutics Inc",
      "marketValue": 52
    },
    {
      "to": 32,
      "from": "Astrazeneca",
      "partnership": "Investment",
      "sector": "Healthcare SaaS",
      "modality": "Digital health tool",
      "companyName": "Huma ",
      "marketValue": 33
    },
    {
      "to": 33,
      "from": "Astrazeneca",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Precision Therapeutics ",
      "companyName": "Target Medicals LLC",
      "marketValue": "NA"
    },
    {
      "to": 34,
      "from": "Astrazeneca",
      "partnership": "Acquisition",
      "sector": "Drug discovery and Development",
      "modality": "Precision Therapeutics ",
      "companyName": "Caelum Biosciences, Inc.",
      "marketValue": 500
    },
    {
      "to": 35,
      "from": "Astrazeneca",
      "partnership": "Acquisition",
      "sector": "Drug discovery and Development",
      "modality": "Precision Therapeutics ",
      "companyName": "Alexion Pharmaceuticals, Inc.",
      "marketValue": 3900
    },
    {
      "to": 36,
      "from": "Astrazeneca",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "RNA Therapeutics",
      "companyName": "Ionis",
      "marketValue": 3.585
    },
    {
      "to": 37,
      "from": "Astrazeneca",
      "partnership": "Partnership",
      "sector": "Drug discovery and Development",
      "modality": "RNA Therapeutics",
      "companyName": "VaxEquity",
      "marketValue": "NA"
    },
    {
      "to": 38,
      "from": "Astrazeneca",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "RNA Therapeutics",
      "companyName": "Accent Therapeutics",
      "marketValue": 55
    },
    {
      "to": 39,
      "from": "Astrazeneca",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "RNA Therapeutics",
      "companyName": "Silence Therapeutics",
      "marketValue": 470
    },
    {
      "to": 40,
      "from": "Astrazeneca",
      "partnership": "Partnership",
      "sector": "Disease Diagnostics and Devices",
      "modality": "Minimal residual disease (MRD) testing",
      "companyName": "ArcherDX",
      "marketValue": "NA"
    },
    {
      "to": 41,
      "from": "Astrazeneca",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Small molecule therapy",
      "companyName": "Dogma Therapeutics",
      "marketValue": "NA"
    },
    {
      "to": 42,
      "from": "Astrazeneca",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Antibody-Drug Conjugate (ADC)",
      "companyName": "Daiichi Sankyo Company, Limited",
      "marketValue": 6000
    },
    {
      "to": 43,
      "from": "Astrazeneca",
      "partnership": "Partnership",
      "sector": "Drug discovery and Development",
      "modality": "In-silico drug discovery",
      "companyName": "BenevolentAI ",
      "marketValue": "NA"
    },
    {
      "to": 44,
      "from": "Astrazeneca",
      "partnership": "Partnership",
      "sector": "Drug Delivery Technology",
      "modality": "Antibody-Drug Conjugate (ADC)",
      "companyName": "Aptamer Group",
      "marketValue": "NA"
    },
    {
      "to": 45,
      "from": "Astrazeneca",
      "partnership": "Partnership",
      "sector": "Drug discovery and Development",
      "modality": "Antibody-Drug Conjugate (ADC)",
      "companyName": "Cancer Research UK",
      "marketValue": "NA"
    },
    {
      "to": 46,
      "from": "Astrazeneca",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Precision Therapeutics ",
      "companyName": "Innate Pharma SA",
      "marketValue": 875
    },
    {
      "to": 47,
      "from": "Astrazeneca",
      "partnership": "Partnership",
      "sector": "Drug discovery and Development",
      "modality": "Gene editing technologies (CRISPR)",
      "companyName": "IGI Research",
      "marketValue": "NA"
    },
    {
      "to": 48,
      "from": "Astrazeneca",
      "partnership": "Partnership",
      "sector": "Drug discovery and Development",
      "modality": "In-silico drug discovery",
      "companyName": "Pelago Bioscience",
      "marketValue": "NA"
    },
    {
      "to": 49,
      "from": "Astrazeneca",
      "partnership": "Partnership",
      "sector": "Drug discovery and Development",
      "modality": "In-silico drug discovery",
      "companyName": "Yiviva ",
      "marketValue": "NA"
    },
    {
      "to": 50,
      "from": "Merck & Co.",
      "partnership": "Acquisition",
      "sector": "Drug discovery and Development",
      "modality": "Precision Therapeutics ",
      "companyName": "Harpoon Therapeutics",
      "marketValue": 680
    },
    {
      "to": 51,
      "from": "Merck & Co.",
      "partnership": "Partnership",
      "sector": "Drug discovery and Development",
      "modality": "Precision Therapeutics ",
      "companyName": "Lava Therapeutics",
      "marketValue": "NA"
    },
    {
      "to": 52,
      "from": "Merck & Co.",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Precision Therapeutics ",
      "companyName": "Evaxion Biotech",
      "marketValue": 5.29
    },
    {
      "to": 53,
      "from": "Merck & Co.",
      "partnership": "Acquisition",
      "sector": "Drug discovery and Development",
      "modality": "Small molecule therapy",
      "companyName": "Caraway Therapeutics",
      "marketValue": 610
    },
    {
      "to": 54,
      "from": "Merck & Co.",
      "partnership": "Acquisition",
      "sector": "Drug discovery and Development",
      "modality": "Precision Therapeutics ",
      "companyName": "Prometheus Biosciences",
      "marketValue": 10800
    },
    {
      "to": 55,
      "from": "Merck & Co.",
      "partnership": "Partnership",
      "sector": "Drug discovery and Development",
      "modality": "Cell therapy",
      "companyName": "Triumvira Immunologics",
      "marketValue": "NA"
    },
    {
      "to": 56,
      "from": "Merck & Co.",
      "partnership": "Partnership",
      "sector": "Drug discovery and Development",
      "modality": "Precision Therapeutics ",
      "companyName": "Phanes Therapeutics, Inc",
      "marketValue": "NA"
    },
    {
      "to": 57,
      "from": "Merck & Co.",
      "partnership": "Partnership",
      "sector": "Drug discovery and Development",
      "modality": "Protein and peptide-based therapeutics",
      "companyName": "IRBM",
      "marketValue": "NA"
    },
    {
      "to": 58,
      "from": "Merck & Co.",
      "partnership": "Partnership",
      "sector": "Drug discovery and Development",
      "modality": "Small molecule therapy",
      "companyName": "HiberCell, Inc.",
      "marketValue": "NA"
    },
    {
      "to": 59,
      "from": "Merck & Co.",
      "partnership": "Partnership",
      "sector": "Drug discovery and Development",
      "modality": "Protein and peptide-based therapeutics",
      "companyName": "BJ Bioscience, Inc.",
      "marketValue": "NA"
    },
    {
      "to": 60,
      "from": "Merck & Co.",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Neuroscience Therapy",
      "companyName": "VectorY Therapeutics",
      "marketValue": 140
    },
    {
      "to": 61,
      "from": "Merck & Co.",
      "partnership": "Partnership",
      "sector": "Drug discovery and Development",
      "modality": "Protein and peptide-based therapeutics",
      "companyName": "Philogen S.p.A",
      "marketValue": "NA"
    },
    {
      "to": 62,
      "from": "Merck & Co.",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Antibody-Drug Conjugate (ADC)",
      "companyName": "Daiichi Sankyo Company, Limited",
      "marketValue": 5500
    },
    {
      "to": 63,
      "from": "Merck & Co.",
      "partnership": "Partnership",
      "sector": "Biotechnology",
      "modality": "AI-powered diagnostics",
      "companyName": "Owkin",
      "marketValue": "NA"
    },
    {
      "to": 64,
      "from": "Merck & Co.",
      "partnership": "Investment",
      "sector": "Biotechnology",
      "modality": "In-silico drug discovery",
      "companyName": "Proxygen ",
      "marketValue": 2550
    },
    {
      "to": 65,
      "from": "Merck & Co.",
      "partnership": "Acquisition",
      "sector": "Drug discovery and Development",
      "modality": "Precision Therapeutics ",
      "companyName": "Imago BioSciences",
      "marketValue": 1350
    },
    {
      "to": 66,
      "from": "Merck & Co.",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Antibody-Drug Conjugate (ADC)",
      "companyName": "Kelun Biotech",
      "marketValue": 9475
    },
    {
      "to": 67,
      "from": "Merck & Co.",
      "partnership": "Investment",
      "sector": "Biotechnology",
      "modality": "RNA Therapeutics",
      "companyName": "Orna Therapeutics",
      "marketValue": 153.6
    },
    {
      "to": 68,
      "from": "Merck & Co.",
      "partnership": "Partnership",
      "sector": "Biotechnology",
      "modality": "Digital health tool",
      "companyName": "Syapse",
      "marketValue": "NA"
    },
    {
      "to": 69,
      "from": "Merck & Co.",
      "partnership": "Partnership",
      "sector": "Drug discovery and Development",
      "modality": "Cytokine based therapeutics",
      "companyName": "TILT Biotherapeutics",
      "marketValue": "NA"
    },
    {
      "to": 70,
      "from": "Merck & Co.",
      "partnership": "Acquisition",
      "sector": "Drug discovery and Development",
      "modality": "Precision Therapeutics ",
      "companyName": "Acceleron Pharma Inc.",
      "marketValue": 11500
    },
    {
      "to": 71,
      "from": "Merck & Co.",
      "partnership": "Acquisition",
      "sector": "Drug discovery and Development",
      "modality": "Cell therapy",
      "companyName": "Pandion Therapeutics, Inc.",
      "marketValue": 1850
    },
    {
      "to": 72,
      "from": "Merck & Co.",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Precision Therapeutics ",
      "companyName": "NGM Biopharmaceuticals",
      "marketValue": 120
    },
    {
      "to": 73,
      "from": "Merck & Co.",
      "partnership": "Partnership",
      "sector": "Drug discovery and Development",
      "modality": "Cell therapy",
      "companyName": "Carisma Therapeutics",
      "marketValue": "NA"
    },
    {
      "to": 74,
      "from": "Merck & Co.",
      "partnership": "Partnership",
      "sector": "Drug discovery and Development",
      "modality": "Precision Therapeutics ",
      "companyName": "Gilead ",
      "marketValue": "NA"
    },
    {
      "to": 75,
      "from": "Merck & Co.",
      "partnership": "Partnership",
      "sector": "Drug discovery and Development",
      "modality": "Gene therapy",
      "companyName": "OncoSec Medical",
      "marketValue": "NA"
    },
    {
      "to": 76,
      "from": "Merck & Co.",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Cytokine based therapeutics",
      "companyName": "Synthekine Inc.",
      "marketValue": 525
    },
    {
      "to": 77,
      "from": "Merck & Co.",
      "partnership": "Partnership",
      "sector": "Drug discovery and Development",
      "modality": "Cell therapy",
      "companyName": "PDS Biotechnology Corp.",
      "marketValue": "NA"
    },
    {
      "to": 78,
      "from": "Merck & Co.",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Precision Therapeutics ",
      "companyName": "Xeris Pharmaceuticals",
      "marketValue": 50
    },
    {
      "to": 79,
      "from": "Merck & Co.",
      "partnership": "Acquisition",
      "sector": "Drug discovery and Development",
      "modality": "Protein and peptide-based therapeutics",
      "companyName": "OncoImmune, Inc.",
      "marketValue": 475
    },
    {
      "to": 80,
      "from": "Merck & Co.",
      "partnership": "Acquisition",
      "sector": "Drug discovery and Development",
      "modality": "Vaccines",
      "companyName": "Themis Bio Holdings LLC",
      "marketValue": "NA"
    },
    {
      "to": 81,
      "from": "Merck & Co.",
      "partnership": "Acquisition",
      "sector": "Drug discovery and Development",
      "modality": "Vaccines",
      "companyName": "VelosBio Inc.",
      "marketValue": 2750
    },
    {
      "to": 82,
      "from": "Merck & Co.",
      "partnership": "Partnership",
      "sector": "Drug discovery and Development",
      "modality": "Cell therapy",
      "companyName": "A2 Bio",
      "marketValue": "NA"
    },
    {
      "to": 83,
      "from": "Merck & Co.",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Precision Therapeutics ",
      "companyName": "Yumanity Therapeutics\n(Kineta)",
      "marketValue": 500
    },
    {
      "to": 84,
      "from": "Merck & Co.",
      "partnership": "Acquisition",
      "sector": "Drug discovery and Development",
      "modality": "Precision Therapeutics ",
      "companyName": "ArQule",
      "marketValue": 2700
    },
    {
      "to": 85,
      "from": "Merck & Co.",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Precision Therapeutics ",
      "companyName": "Ridgeback Biotherapeutics LP",
      "marketValue": "NA"
    },
    {
      "to": 86,
      "from": "Merck & Co.",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Small molecule therapy",
      "companyName": "Astex Pharmaceuticals ",
      "marketValue": 535
    },
    {
      "to": 87,
      "from": "Merck & Co.",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Protein and peptide-based therapeutics",
      "companyName": "Hanmi Pharmaceutical",
      "marketValue": 870
    },
    {
      "to": 88,
      "from": "Merck & Co.",
      "partnership": "Partnership",
      "sector": "Drug discovery and Development",
      "modality": "Vaccines",
      "companyName": "Bill & Melinda Gates Foundation",
      "marketValue": "NA"
    },
    {
      "to": 89,
      "from": "Merck & Co.",
      "partnership": "Acquisition",
      "sector": "Drug discovery and Development",
      "modality": "Precision Therapeutics ",
      "companyName": "Calporta Therapeutics, Inc.",
      "marketValue": 576
    },
    {
      "to": 90,
      "from": "Merck & Co.",
      "partnership": "Acquisition",
      "sector": "Biotechnology",
      "modality": "Cell therapy",
      "companyName": "Immune Design Corp.",
      "marketValue": 300
    },
    {
      "to": 91,
      "from": "Merck & Co.",
      "partnership": "Acquisition",
      "sector": "Drug discovery and Development",
      "modality": "Cytokine based therapeutics",
      "companyName": "Tilos Therapeutics, Inc.",
      "marketValue": 773
    },
    {
      "to": 92,
      "from": "Merck & Co.",
      "partnership": "Investment",
      "sector": "Biotechnology",
      "modality": "Microbiome-based therapies",
      "companyName": "4D pharma",
      "marketValue": 341
    },
    {
      "to": 93,
      "from": "Merck & Co.",
      "partnership": "Acquisition",
      "sector": "Drug discovery and Development",
      "modality": "Precision Therapeutics ",
      "companyName": "Peloton Therapeutics",
      "marketValue": 1150
    },
    {
      "to": 94,
      "from": "Merck & Co.",
      "partnership": "Partnership",
      "sector": "Drug discovery and Development",
      "modality": "Targeted Alpha Therapies (TATs)",
      "companyName": "Fusion Pharmaceuticals",
      "marketValue": "NA"
    },
    {
      "to": 95,
      "from": "Merck & Co.",
      "partnership": "Acquisition",
      "sector": "Drug discovery and Development",
      "modality": "Precision Therapeutics ",
      "companyName": "Viralytics Limited",
      "marketValue": 394
    },
    {
      "to": 96,
      "from": "Merck & Co.",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Cell therapy",
      "companyName": "ImaginAb",
      "marketValue": "NA"
    },
    {
      "to": 97,
      "from": "Merck & Co.",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Combination Therapy",
      "companyName": "Eisai",
      "marketValue": 5700
    },
    {
      "to": 98,
      "from": "Merck & Co.",
      "partnership": "Partnership",
      "sector": "Drug discovery and Development",
      "modality": "Vaccines",
      "companyName": "Instituto Butantan",
      "marketValue": "NA"
    },
    {
      "to": 99,
      "from": "Merck & Co.",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "RNA Therapeutics",
      "companyName": "Moderna Therapeutics ",
      "marketValue": 125
    },
    {
      "to": 100,
      "from": "AbbVie",
      "partnership": "Acquisition",
      "sector": "Drug discovery and Development",
      "modality": "Multiple modalities ",
      "companyName": "Allergan",
      "marketValue": 63000
    },
    {
      "to": 101,
      "from": "AbbVie",
      "partnership": "Acquisition",
      "sector": "Drug discovery and Development",
      "modality": "Neuroscience Therapy",
      "companyName": "Mitokinin",
      "marketValue": 655
    },
    {
      "to": 102,
      "from": "AbbVie",
      "partnership": "Acquisition",
      "sector": "Drug discovery and Development",
      "modality": "Antibody-Drug Conjugate (ADC)",
      "companyName": "ImmunoGen",
      "marketValue": 10100
    },
    {
      "to": 103,
      "from": "AbbVie",
      "partnership": "Partnership",
      "sector": "Drug discovery and Development",
      "modality": "Tissue engineering",
      "companyName": "BioMed X Institute",
      "marketValue": "NA"
    },
    {
      "to": 104,
      "from": "AbbVie",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Neuroscience Therapy",
      "companyName": "Calico Life Sciences",
      "marketValue": 1000
    },
    {
      "to": 105,
      "from": "AbbVie",
      "partnership": "Partnership",
      "sector": "Drug discovery and Development",
      "modality": "Genomics analysis",
      "companyName": "M42",
      "marketValue": "NA"
    },
    {
      "to": 106,
      "from": "AbbVie",
      "partnership": "Partnership",
      "sector": "Drug discovery and Development",
      "modality": "Small molecule therapy",
      "companyName": "Jacobio Pharmaceuticals",
      "marketValue": "NA"
    },
    {
      "to": 107,
      "from": "AbbVie",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Cell therapy",
      "companyName": "Umoja Biopharma",
      "marketValue": 1440
    },
    {
      "to": 108,
      "from": "AbbVie",
      "partnership": "Acquisition",
      "sector": "Drug discovery and Development",
      "modality": "Gene editing technologies (CRISPR)",
      "companyName": "Caribou Biosciences",
      "marketValue": 340
    },
    {
      "to": 109,
      "from": "AbbVie",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Gene therapy",
      "companyName": "Regenxbio",
      "marketValue": 1750
    },
    {
      "to": 110,
      "from": "AbbVie",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Gene Therapy",
      "companyName": "Capsida Biotherapeutics Inc.",
      "marketValue": 665
    },
    {
      "to": 111,
      "from": "AbbVie",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Gene therapy",
      "companyName": "Voyager Therapeutics",
      "marketValue": 224
    },
    {
      "to": 112,
      "from": "AbbVie",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "In-silico drug discovery",
      "companyName": "Atomwise",
      "marketValue": 123
    },
    {
      "to": 113,
      "from": "AbbVie",
      "partnership": "Acquisition",
      "sector": "Drug discovery and Development",
      "modality": "Protein and peptide-based therapeutics",
      "companyName": "DJS Antibodies",
      "marketValue": 255
    },
    {
      "to": 114,
      "from": "AbbVie",
      "partnership": "Acquisition",
      "sector": "Drug discovery and Development",
      "modality": "Small molecule therapy",
      "companyName": "Mavupharma",
      "marketValue": "NA"
    },
    {
      "to": 115,
      "from": "AbbVie",
      "partnership": "Partnership",
      "sector": "Drug discovery and Development",
      "modality": "Small molecule therapy",
      "companyName": "Scripps Research",
      "marketValue": "NA"
    },
    {
      "to": 116,
      "from": "AbbVie",
      "partnership": "Partnership",
      "sector": "Drug discovery and Development",
      "modality": "Targeted Protein Degradation",
      "companyName": "Frontier Medicines",
      "marketValue": "NA"
    },
    {
      "to": 117,
      "from": "AbbVie",
      "partnership": "Partnership",
      "sector": "Drug discovery and Development",
      "modality": "Precision Therapeutics ",
      "companyName": "Leukemia & Lymphoma Society",
      "marketValue": "NA"
    },
    {
      "to": 118,
      "from": "AbbVie",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Small molecule therapy",
      "companyName": "HotSpot Therapeutics",
      "marketValue": 335
    },
    {
      "to": 119,
      "from": "AbbVie",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "In-silico drug discovery",
      "companyName": "BigHat Biosciences",
      "marketValue": 355
    },
    {
      "to": 120,
      "from": "AbbVie",
      "partnership": "Partnership",
      "sector": "Drug discovery and Development",
      "modality": "AI in clinical trials",
      "companyName": "Caris Life Sciences and ConcertAI",
      "marketValue": "NA"
    },
    {
      "to": 121,
      "from": "AbbVie",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Targeted Protein Degradation",
      "companyName": "I-Mab",
      "marketValue": 1940
    },
    {
      "to": 122,
      "from": "AbbVie",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Precision Therapeutics ",
      "companyName": "Cugene Inc.",
      "marketValue": 48.5
    },
    {
      "to": 123,
      "from": "AbbVie",
      "partnership": "Partnership",
      "sector": "Drug discovery and Development",
      "modality": "In-silico drug discovery",
      "companyName": "AbCellera Biologics Inc.",
      "marketValue": "NA"
    },
    {
      "to": 124,
      "from": "AbbVie",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Small molecule therapy",
      "companyName": "Morphic Therapeutic",
      "marketValue": 100
    },
    {
      "to": 125,
      "from": "AbbVie",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Antibody-Drug Conjugate (ADC)",
      "companyName": "Disco Pharmaceuticals",
      "marketValue": 22
    },
    {
      "to": 126,
      "from": "AbbVie",
      "partnership": "Partnership",
      "sector": "Drug discovery and Development",
      "modality": "Multiple modalities ",
      "companyName": "Calibr",
      "marketValue": "NA"
    },
    {
      "to": 127,
      "from": "AbbVie",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "RNA Therapeutics",
      "companyName": "Anima Biotech",
      "marketValue": 582
    },
    {
      "to": 128,
      "from": "AbbVie",
      "partnership": "Investment",
      "sector": "Drug Delivery Technology",
      "modality": "Therapeutic devices",
      "companyName": "Lyndra Therapeutics",
      "marketValue": 101
    },
    {
      "to": 129,
      "from": "AbbVie",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Small molecule therapy",
      "companyName": "Lupin",
      "marketValue": 30
    },
    {
      "to": 130,
      "from": "AbbVie",
      "partnership": "Partnership",
      "sector": "Drug discovery and Development",
      "modality": "Precision Therapeutics ",
      "companyName": "Immunome",
      "marketValue": "NA"
    },
    {
      "to": 131,
      "from": "AbbVie",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Small molecule therapy",
      "companyName": "Caraway Therapeutics",
      "marketValue": 267
    },
    {
      "to": 132,
      "from": "AbbVie",
      "partnership": "Acquisition",
      "sector": "Drug discovery and Development",
      "modality": "Neuroscience Therapy",
      "companyName": "Cerevel Therapeutics",
      "marketValue": 8700
    },
    {
      "to": 133,
      "from": "AbbVie",
      "partnership": "Investment",
      "sector": "Medical Devices & Equipment",
      "modality": "Therapeutic devices",
      "companyName": "iSTAR Medical",
      "marketValue": 535
    },
    {
      "to": 134,
      "from": "AbbVie",
      "partnership": "Acquisition",
      "sector": "Drug discovery and Development",
      "modality": "Small molecule therapy",
      "companyName": "Syndesi Therapeutics",
      "marketValue": 1000
    },
    {
      "to": 135,
      "from": "AbbVie",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Bispecific antibodies",
      "companyName": "Teneobio Inc. ",
      "marketValue": 90
    },
    {
      "to": 136,
      "from": "AbbVie",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Precision Therapeutics ",
      "companyName": "Kojin TX",
      "marketValue": 60
    },
    {
      "to": 137,
      "from": "AbbVie",
      "partnership": "Partnership",
      "sector": "Drug discovery and Development",
      "modality": "Precision Therapeutics ",
      "companyName": "Tizona Therapeutics",
      "marketValue": "NA"
    },
    {
      "to": 138,
      "from": "AbbVie",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Small molecule therapy",
      "companyName": "Galapagos (cystic fibrosis pipeline)",
      "marketValue": 45
    },
    {
      "to": 139,
      "from": "AbbVie",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Cell therapy",
      "companyName": "ArgenX",
      "marketValue": 625
    },
    {
      "to": 140,
      "from": "AbbVie",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "RNA Therapeutics",
      "companyName": "Accent Therapeutics",
      "marketValue": 63
    },
    {
      "to": 141,
      "from": "AbbVie",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Targeted Protein Degradation",
      "companyName": "Ambagon Therapeutics",
      "marketValue": 85
    },
    {
      "to": 142,
      "from": "AbbVie",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "RNA Therapeutics",
      "companyName": "Artios Pharma Limited",
      "marketValue": 84
    },
    {
      "to": 143,
      "from": "AbbVie",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Precision Therapeutics ",
      "companyName": "Enthera Pharmaceuticals",
      "marketValue": 38.5
    },
    {
      "to": 144,
      "from": "AbbVie",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Small Molecule Therapy",
      "companyName": "Jnana Therapeutics",
      "marketValue": 50
    },
    {
      "to": 145,
      "from": "AbbVie",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Neuroscience Therapy",
      "companyName": "Nitrase Therapeutics (previously Nitrome Biosciences)",
      "marketValue": 38
    },
    {
      "to": 146,
      "from": "AbbVie",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Glyco-immunology based therapeutics",
      "companyName": "Palleon Pharmaceuticals",
      "marketValue": 100
    },
    {
      "to": 147,
      "from": "AbbVie",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Small molecule therapy",
      "companyName": "Quanta Therapeutics",
      "marketValue": 50
    },
    {
      "to": 148,
      "from": "AbbVie",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "RNA Therapeutics",
      "companyName": "Ribometrix",
      "marketValue": 30
    },
    {
      "to": 149,
      "from": "AbbVie",
      "partnership": "Investment",
      "sector": "Biotechnology",
      "modality": "Therapeutic devices",
      "companyName": "Stemson Therapeutics",
      "marketValue": 15
    },
    {
      "to": 150,
      "from": "AbbVie",
      "partnership": "Partnership",
      "sector": "Drug discovery and Development",
      "modality": "Precision Therapeutics ",
      "companyName": "Trishula Therapeutics",
      "marketValue": "NA"
    },
    {
      "to": 151,
      "from": "Merck & Co.",
      "partnership": "Investment",
      "sector": "Biotechnology",
      "modality": "In-silico drug discovery",
      "companyName": "Unnatural Products",
      "marketValue": 32
    },
    {
      "to": 152,
      "from": "Merck & Co.",
      "partnership": "Investment",
      "sector": "Biotechnology",
      "modality": "In-silico drug discovery",
      "companyName": "Aitia ",
      "marketValue": 28
    },
    {
      "to": 153,
      "from": "Merck & Co.",
      "partnership": "Investment",
      "sector": "Biotechnology",
      "modality": "In-silico drug discovery",
      "companyName": "ClearDATA",
      "marketValue": 26
    },
    {
      "to": 154,
      "from": "Merck & Co.",
      "partnership": "Investment",
      "sector": "Biotechnology",
      "modality": "In-silico drug discovery",
      "companyName": "Clinithink",
      "marketValue": "NA"
    },
    {
      "to": 155,
      "from": "Merck & Co.",
      "partnership": "Investment",
      "sector": "Biotechnology",
      "modality": "In-silico drug discovery",
      "companyName": "Pragma Bio",
      "marketValue": 10
    },
    {
      "to": 156,
      "from": "Novartis",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Precision Therapeutics ",
      "companyName": "Center for Biologics Technical Development",
      "marketValue": 122
    },
    {
      "to": 157,
      "from": "Novartis",
      "partnership": "Acquisition",
      "sector": "Drug discovery and Development",
      "modality": "Precision Therapeutics ",
      "companyName": "Chinook Therapeutics",
      "marketValue": 3500
    },
    {
      "to": 158,
      "from": "Novartis",
      "partnership": "Acquisition",
      "sector": "Drug discovery and Development",
      "modality": "Precision Therapeutics ",
      "companyName": "Xiidra",
      "marketValue": 5300
    },
    {
      "to": 159,
      "from": "Novartis",
      "partnership": "Partnership",
      "sector": "Drug discovery and Development",
      "modality": "Precision Therapeutics ",
      "companyName": "Pfizer",
      "marketValue": "NA"
    },
    {
      "to": 160,
      "from": "Novartis",
      "partnership": "Partnership",
      "sector": "Healthcare SaaS",
      "modality": "Digital health tool",
      "companyName": "Dawn Health",
      "marketValue": "NA"
    },
    {
      "to": 161,
      "from": "Novartis",
      "partnership": "Partnership",
      "sector": "Drug discovery and Development",
      "modality": "RNA Therapeutics",
      "companyName": "Alnylam Pharmaceuticals",
      "marketValue": "NA"
    },
    {
      "to": 162,
      "from": "Novartis",
      "partnership": "Partnership",
      "sector": "Drug discovery and Development",
      "modality": "Precision Therapeutics ",
      "companyName": "Drugs for Neglected Diseases initiative",
      "marketValue": "NA"
    },
    {
      "to": 163,
      "from": "Novartis",
      "partnership": "Acquisition",
      "sector": "Drug manufacturing",
      "modality": "Cell therapy",
      "companyName": "CellforCure",
      "marketValue": "NA"
    },
    {
      "to": 164,
      "from": "Novartis",
      "partnership": "Partnership",
      "sector": "Drug discovery and Development",
      "modality": "Cell therapy",
      "companyName": "University of Pennsylvania",
      "marketValue": "NA"
    },
    {
      "to": 165,
      "from": "Novartis",
      "partnership": "Acquisition",
      "sector": "Drug discovery and Development",
      "modality": "Gene therapy",
      "companyName": "Gyroscope Therapeutics",
      "marketValue": 1500
    },
    {
      "to": 166,
      "from": "Novartis",
      "partnership": "Acquisition",
      "sector": "Drug discovery and Development",
      "modality": "Gene therapy",
      "companyName": "AveXis, Inc.",
      "marketValue": 8700
    },
    {
      "to": 167,
      "from": "Novartis",
      "partnership": "Acquisition",
      "sector": "Drug discovery and Development",
      "modality": "Gene therapy",
      "companyName": "Vedere Bio",
      "marketValue": 280
    },
    {
      "to": 168,
      "from": "Novartis",
      "partnership": "Partnership",
      "sector": "Drug discovery and Development",
      "modality": "Gene therapy",
      "companyName": "Bill & Melinda Gates Foundation",
      "marketValue": "NA"
    },
    {
      "to": 169,
      "from": "Novartis",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Gene therapy",
      "companyName": "Voyager Therapeutics",
      "marketValue": 1200
    },
    {
      "to": 170,
      "from": "Novartis",
      "partnership": "Partnership",
      "sector": "Drug discovery and Development",
      "modality": "Gene therapy",
      "companyName": "Sangamo Therapeutics",
      "marketValue": "NA"
    },
    {
      "to": 171,
      "from": "Novartis",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "AI in clinical trials",
      "companyName": "Yseop",
      "marketValue": "NA"
    },
    {
      "to": 172,
      "from": "Novartis",
      "partnership": "Investment",
      "sector": "Biotechnology",
      "modality": "In-silico drug discovery",
      "companyName": "Isomorphic Labs",
      "marketValue": 37.5
    },
    {
      "to": 173,
      "from": "Novartis",
      "partnership": "Partnership",
      "sector": "Drug discovery and Development",
      "modality": "Precision Therapeutics ",
      "companyName": "BioCurate Pty Ltd",
      "marketValue": "NA"
    },
    {
      "to": 174,
      "from": "Novartis",
      "partnership": "Investment",
      "sector": "Healthcare SaaS",
      "modality": "Digital health tool",
      "companyName": "Koneksa",
      "marketValue": 45
    },
    {
      "to": 175,
      "from": "Novartis",
      "partnership": "Acquisition",
      "sector": "Drug discovery and Development",
      "modality": "Protein and peptide-based therapeutics",
      "companyName": "Calypso Biotech BV",
      "marketValue": 425
    },
    {
      "to": 176,
      "from": "Novartis",
      "partnership": "Partnership",
      "sector": "Drug discovery and Development",
      "modality": "AI in clinical trials",
      "companyName": "University of Oxford",
      "marketValue": "NA"
    },
    {
      "to": 177,
      "from": "Novartis",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Protein and peptide-based therapeutics",
      "companyName": "BeiGene",
      "marketValue": 2895
    },
    {
      "to": 178,
      "from": "Novartis",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Cell therapy",
      "companyName": "Mesoblast Ltd.",
      "marketValue": 50
    },
    {
      "to": 179,
      "from": "Novartis",
      "partnership": "Acquisition",
      "sector": "Drug discovery and Development",
      "modality": "RNA Therapeutics",
      "companyName": "DTx Pharm",
      "marketValue": 500
    },
    {
      "to": 180,
      "from": "Novartis",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Radiopharmaceutical therapy",
      "companyName": "Bicycle Therapeutics",
      "marketValue": 1750
    },
    {
      "to": 181,
      "from": "Novartis",
      "partnership": "Partnership",
      "sector": "Drug manufacturing",
      "modality": "Cell therapy",
      "companyName": "Fraunhofer IZI",
      "marketValue": "NA"
    },
    {
      "to": 182,
      "from": "Novartis",
      "partnership": "Investment",
      "sector": "Drug Delivery Technology",
      "modality": "Therapeutic devices",
      "companyName": "Credence MedSystems",
      "marketValue": "NA"
    },
    {
      "to": 183,
      "from": "Novartis",
      "partnership": "Acquisition",
      "sector": "Drug Delivery Technology",
      "modality": "Therapeutic devices",
      "companyName": "Kedalion Therapeutics",
      "marketValue": "NA"
    },
    {
      "to": 184,
      "from": "Novartis",
      "partnership": "Partnership",
      "sector": "Drug discovery and Development",
      "modality": "In-silico drug discovery",
      "companyName": "AbCellera Biologics Inc.",
      "marketValue": "NA"
    },
    {
      "to": 185,
      "from": "Novartis",
      "partnership": "Acquisition",
      "sector": "Drug discovery and Development",
      "modality": "Small molecule therapy",
      "companyName": "The Medicines Company",
      "marketValue": 9700
    },
    {
      "to": 186,
      "from": "Novartis",
      "partnership": "Partnership",
      "sector": "Drug discovery and Development",
      "modality": "Digital health tool",
      "companyName": "Microsoft",
      "marketValue": "NA"
    },
    {
      "to": 187,
      "from": "Novartis",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Neuroscience Therapy",
      "companyName": "UCB",
      "marketValue": 1650
    },
    {
      "to": 188,
      "from": "Novartis",
      "partnership": "Investment",
      "sector": "Disease Diagnostics and Devices",
      "modality": "Digital health tool",
      "companyName": "Octave Bioscience",
      "marketValue": 30
    },
    {
      "to": 189,
      "from": "Novartis",
      "partnership": "Investment",
      "sector": "Drug manufacturing",
      "modality": "Precision Therapeutics ",
      "companyName": "The University of Manchester",
      "marketValue": 3.5
    },
    {
      "to": 190,
      "from": "Novartis",
      "partnership": "Partnership",
      "sector": "Drug manufacturing",
      "modality": "Cell therapy",
      "companyName": "Carisma Therapeutics",
      "marketValue": "NA"
    },
    {
      "to": 191,
      "from": "Novartis",
      "partnership": "Investment",
      "sector": "Disease Diagnostics and Devices",
      "modality": "Gene Editing Technologies (CRISPR)",
      "companyName": "Precision BioSciences",
      "marketValue": 1475
    },
    {
      "to": 192,
      "from": "Novartis",
      "partnership": "Partnership",
      "sector": "Biotechnology",
      "modality": "In-silico drug discovery",
      "companyName": "Elsevier",
      "marketValue": "NA"
    },
    {
      "to": 193,
      "from": "Novartis",
      "partnership": "Partnership",
      "sector": "Disease Diagnostics and Devices",
      "modality": "Precision Therapeutics ",
      "companyName": "Becton, Dickinson and Company",
      "marketValue": "NA"
    },
    {
      "to": 194,
      "from": "Novartis",
      "partnership": "Partnership",
      "sector": "Disease Diagnostics and Devices",
      "modality": "Precision Therapeutics ",
      "companyName": "Celcuity",
      "marketValue": "NA"
    },
    {
      "to": 195,
      "from": "Novartis",
      "partnership": "Acquisition",
      "sector": "Drug discovery and Development",
      "modality": "Precision Therapeutics ",
      "companyName": "SanReno Therapeutics",
      "marketValue": "NA"
    },
    {
      "to": 196,
      "from": "Novartis",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Gene therapy",
      "companyName": "Avrobio",
      "marketValue": 87.5
    },
    {
      "to": 197,
      "from": "Novartis",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Small molecule therapy",
      "companyName": "Flare Therapeutics",
      "marketValue": 123
    },
    {
      "to": 198,
      "from": "Novartis",
      "partnership": "Investment",
      "sector": "Disease Diagnostics and Devices",
      "modality": "Digital health tool",
      "companyName": "Deciphex",
      "marketValue": 11.5
    },
    {
      "to": 199,
      "from": "Novartis",
      "partnership": "Investment",
      "sector": "Healthcare SaaS",
      "modality": "Digital health tool",
      "companyName": "Holmusk",
      "marketValue": 45
    },
    {
      "to": 200,
      "from": "Novartis",
      "partnership": "Investment",
      "sector": "Biotechnology",
      "modality": "In-silico drug discovery",
      "companyName": "Orionis Biosciences",
      "marketValue": "NA"
    },
    {
      "to": 201,
      "from": "Novartis",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Radiopharmaceutical therapy",
      "companyName": "Aktis Oncology",
      "marketValue": 72
    },
    {
      "to": 202,
      "from": "Novartis",
      "partnership": "Investment",
      "sector": "Disease Diagnostics and Devices",
      "modality": "AI-powered diagnostics",
      "companyName": "Cleerly",
      "marketValue": 223
    },
    {
      "to": 203,
      "from": "Novartis",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Therapeutics for Food allergy",
      "companyName": "Alladapt Immunotherapeutics",
      "marketValue": 119
    },
    {
      "to": 204,
      "from": "Novartis",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Protein and peptide-based therapeutics",
      "companyName": "Dunad Therapeutics",
      "marketValue": 1324
    },
    {
      "to": 205,
      "from": "Novartis",
      "partnership": "Acquisition",
      "sector": "Drug discovery and Development",
      "modality": "Gene therapy",
      "companyName": "Arctos Medical",
      "marketValue": "NA"
    },
    {
      "to": 206,
      "from": "Novartis",
      "partnership": "Partnership",
      "sector": "Drug discovery and Development",
      "modality": "Genomics analysis",
      "companyName": "SomaLogic",
      "marketValue": "NA"
    },
    {
      "to": 207,
      "from": "Novartis",
      "partnership": "Investment",
      "sector": "Medical Devices & Equipment",
      "modality": "Non-invasive healthcare devices",
      "companyName": "Dopavision",
      "marketValue": 13.2
    },
    {
      "to": 208,
      "from": "Novartis",
      "partnership": "Acquisition",
      "sector": "Drug discovery and Development",
      "modality": "Neuroscience Therapy",
      "companyName": "Cadent Therapeutics",
      "marketValue": 770
    },
    {
      "to": 209,
      "from": "Novartis",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Cell therapy",
      "companyName": "TScan Therapeutics",
      "marketValue": 30
    },
    {
      "to": 210,
      "from": "Novartis",
      "partnership": "Investment",
      "sector": "Healthcare SaaS",
      "modality": "Digital health tool",
      "companyName": "Aspen RxHealth",
      "marketValue": 23
    },
    {
      "to": 211,
      "from": "Novartis",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Protein and peptide-based therapeutics",
      "companyName": "Molecular Partners",
      "marketValue": 241.5
    },
    {
      "to": 212,
      "from": "Novartis",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Small molecule therapy",
      "companyName": "Pliant Therapeutics",
      "marketValue": 80
    },
    {
      "to": 213,
      "from": "Novartis",
      "partnership": "Acquisition",
      "sector": "Medical Devices & Equipment",
      "modality": "Digital health tool",
      "companyName": "Amblyotech",
      "marketValue": "NA"
    },
    {
      "to": 214,
      "from": "Novartis",
      "partnership": "Partnership",
      "sector": "Drug discovery and Development",
      "modality": "Precision Therapeutics ",
      "companyName": "Forendo Pharma",
      "marketValue": "NA"
    },
    {
      "to": 215,
      "from": "Novartis",
      "partnership": "Investment",
      "sector": "Drug Delivery Technology",
      "modality": "Therapeutic devices",
      "companyName": "SiO2 Medical Products",
      "marketValue": "NA"
    },
    {
      "to": 216,
      "from": "Novartis",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Precision Therapeutics ",
      "companyName": "Iconic Therapeutics",
      "marketValue": "NA"
    },
    {
      "to": 217,
      "from": "Novartis",
      "partnership": "Investment",
      "sector": "Healthcare SaaS",
      "modality": "Digital health tool",
      "companyName": "Xealth",
      "marketValue": 11
    },
    {
      "to": 218,
      "from": "Novartis",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Small molecule therapy",
      "companyName": "Ayala Pharmaceuticals",
      "marketValue": 10
    },
    {
      "to": 219,
      "from": "Novartis",
      "partnership": "Acquisition",
      "sector": "Drug discovery and Development",
      "modality": "Small molecule therapy",
      "companyName": "IFM Tre",
      "marketValue": 1575
    },
    {
      "to": 220,
      "from": "Novartis",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Precision Therapeutics ",
      "companyName": "Anthos Therapeutics",
      "marketValue": "NA"
    },
    {
      "to": 221,
      "from": "Novartis",
      "partnership": "Acquisition",
      "sector": "Drug discovery and Development",
      "modality": "Radiopharmaceutical therapy",
      "companyName": "Endocyte",
      "marketValue": 2100
    },
    {
      "to": 222,
      "from": "Novartis",
      "partnership": "Investment",
      "sector": "Healthcare SaaS",
      "modality": "Digital health tool",
      "companyName": "RxLightning",
      "marketValue": 17.5
    },
    {
      "to": 223,
      "from": "Novartis",
      "partnership": "Partnership",
      "sector": "Healthcare SaaS",
      "modality": "Digital health tool",
      "companyName": "Pear Therapeutics",
      "marketValue": "NA"
    },
    {
      "to": 224,
      "from": "Novartis",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Small molecule therapy",
      "companyName": "Enterprise Therapeutics",
      "marketValue": 33.1
    },
    {
      "to": 225,
      "from": "Novartis",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Therapeutics for Food allergy",
      "companyName": "Aravax",
      "marketValue": 42
    },
    {
      "to": 226,
      "from": "Novartis",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Precision Therapeutics ",
      "companyName": "Hyku Biosciences",
      "marketValue": 56
    },
    {
      "to": 227,
      "from": "Novartis",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Small molecule therapy",
      "companyName": "FORE Biotherapeutics",
      "marketValue": 75
    },
    {
      "to": 228,
      "from": "Novartis",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Antibody-Drug Conjugate (ADC)",
      "companyName": "Tagworks Pharmaceuticals",
      "marketValue": 65
    },
    {
      "to": 229,
      "from": "Novartis",
      "partnership": "Partnership",
      "sector": "Drug discovery and Development",
      "modality": "Antibody-Drug Conjugate (ADC)",
      "companyName": "Oculis",
      "marketValue": "NA"
    },
    {
      "to": 230,
      "from": "Novartis",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Antibody-Drug Conjugate (ADC)",
      "companyName": "Catalym",
      "marketValue": 49
    },
    {
      "to": 231,
      "from": "Novartis",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Cell therapy",
      "companyName": "Capstan Therapeutics",
      "marketValue": 165
    },
    {
      "to": 232,
      "from": "Novartis",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Gene therapy",
      "companyName": "SpliceBio",
      "marketValue": 55
    },
    {
      "to": 233,
      "from": "Novartis",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Precision Therapeutics ",
      "companyName": "Epsilogen",
      "marketValue": 40.9
    },
    {
      "to": 234,
      "from": "Bristol-Myers Squibb",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "In-silico drug discovery",
      "companyName": "VantAI",
      "marketValue": 674
    },
    {
      "to": 235,
      "from": "Bristol-Myers Squibb",
      "partnership": "Acquisition",
      "sector": "Drug discovery and Development",
      "modality": "Precision Therapeutics ",
      "companyName": "Mirati Therapeutics",
      "marketValue": 5800
    },
    {
      "to": 236,
      "from": "Bristol-Myers Squibb",
      "partnership": "Acquisition",
      "sector": "Drug discovery and Development",
      "modality": "Neuroscience Therapy",
      "companyName": "Karuna Therapeutics",
      "marketValue": 14000
    },
    {
      "to": 237,
      "from": "Bristol-Myers Squibb",
      "partnership": "Partnership",
      "sector": "Drug discovery and Development",
      "modality": "Gene editing technologies (CRISPR)",
      "companyName": "MEDiC Life Sciences",
      "marketValue": "NA"
    },
    {
      "to": 238,
      "from": "Bristol-Myers Squibb",
      "partnership": "Partnership",
      "sector": "Drug discovery and Development",
      "modality": "Precision Therapeutics ",
      "companyName": "Karyopharm Therapeutics",
      "marketValue": "NA"
    },
    {
      "to": 239,
      "from": "Bristol-Myers Squibb",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Radiopharmaceutical therapy",
      "companyName": "Ratio Therapeutics",
      "marketValue": 50
    },
    {
      "to": 240,
      "from": "Bristol-Myers Squibb",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "RNA Therapeutics",
      "companyName": "Avidity Biosciences",
      "marketValue": 2300
    },
    {
      "to": 241,
      "from": "Bristol-Myers Squibb",
      "partnership": "Acquisition",
      "sector": "Drug discovery and Development",
      "modality": "Radiopharmaceutical therapy",
      "companyName": "RayzeBio",
      "marketValue": 4100
    },
    {
      "to": 242,
      "from": "Bristol-Myers Squibb",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Precision Therapeutics ",
      "companyName": "EvolveImmune Therapeutics",
      "marketValue": 37
    },
    {
      "to": 243,
      "from": "Bristol-Myers Squibb",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Precision Therapeutics ",
      "companyName": "Q32 Bio",
      "marketValue": 42
    },
    {
      "to": 244,
      "from": "Bristol-Myers Squibb",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "in vitro diagnostic (IVD) genome testing",
      "companyName": "Precede Biosciences ",
      "marketValue": 57
    },
    {
      "to": 245,
      "from": "Bristol-Myers Squibb",
      "partnership": "Partnership",
      "sector": "Drug discovery and Development",
      "modality": "Small molecule therapy",
      "companyName": "Terray Therapeutics",
      "marketValue": "NA"
    },
    {
      "to": 246,
      "from": "Bristol-Myers Squibb",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Bispecific antibodies",
      "companyName": "Zenas BioPharma ",
      "marketValue": 50
    },
    {
      "to": 247,
      "from": "Bristol-Myers Squibb",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Antibody-Drug Conjugate (ADC)",
      "companyName": "Orum Therapeutics",
      "marketValue": 280
    },
    {
      "to": 248,
      "from": "Bristol-Myers Squibb",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Antibody-Drug Conjugate (ADC)",
      "companyName": "Tubulis",
      "marketValue": 1022.75
    },
    {
      "to": 249,
      "from": "Bristol-Myers Squibb",
      "partnership": "Partnership",
      "sector": "Drug discovery and Development",
      "modality": "Small molecule therapy",
      "companyName": "CHARM Therapeutics",
      "marketValue": "NA"
    },
    {
      "to": 250,
      "from": "Bristol-Myers Squibb",
      "partnership": "Investment",
      "sector": "Drug manufacturing",
      "modality": " Automated drug manufacturing technology",
      "companyName": "Cellares",
      "marketValue": 255
    },
    {
      "to": 251,
      "from": "Bristol-Myers Squibb",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Cell therapy",
      "companyName": "Immatics",
      "marketValue": 760
    },
    {
      "to": 252,
      "from": "Bristol-Myers Squibb",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Cell therapy",
      "companyName": "GentiBio",
      "marketValue": 1900
    },
    {
      "to": 253,
      "from": "Bristol-Myers Squibb",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Precision Therapeutics ",
      "companyName": "Volastra Therapeutics",
      "marketValue": 1130
    },
    {
      "to": 254,
      "from": "Bristol-Myers Squibb",
      "partnership": "Partnership",
      "sector": "Drug discovery and Development",
      "modality": "In-silico drug discovery",
      "companyName": "Envisagenics",
      "marketValue": "NA"
    },
    {
      "to": 255,
      "from": "Bristol-Myers Squibb",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Targeted Protein Degradation",
      "companyName": "SyntheX",
      "marketValue": 550
    },
    {
      "to": 256,
      "from": "Bristol-Myers Squibb",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Cell therapy",
      "companyName": "Century Therapeutics",
      "marketValue": 3150
    },
    {
      "to": 257,
      "from": "Bristol-Myers Squibb",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "AI in clinical trials",
      "companyName": "Paradigm",
      "marketValue": "NA"
    },
    {
      "to": 258,
      "from": "Bristol-Myers Squibb",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Small molecule therapy",
      "companyName": "K36 Therapeutics",
      "marketValue": 70
    },
    {
      "to": 259,
      "from": "Bristol-Myers Squibb",
      "partnership": "Investment",
      "sector": "Drug Delivery Technology",
      "modality": "Gene delivery vehicles ",
      "companyName": "iVexSol",
      "marketValue": 23.8
    },
    {
      "to": 260,
      "from": "Bristol-Myers Squibb",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Gene editing technologies (CRISPR)",
      "companyName": "Metagenomi Technologies",
      "marketValue": 175
    },
    {
      "to": 261,
      "from": "Bristol-Myers Squibb",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Neuroscience Therapy",
      "companyName": "Cajal Neuroscience",
      "marketValue": 96
    },
    {
      "to": 262,
      "from": "Bristol-Myers Squibb",
      "partnership": "Investment",
      "sector": "Drug discovery and development",
      "modality": "Cell therapy",
      "companyName": "ArsenalBio",
      "marketValue": 220
    },
    {
      "to": 263,
      "from": "Bristol-Myers Squibb",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Neuroscience Therapy",
      "companyName": "Autobahn Therapeutics",
      "marketValue": 32.7
    },
    {
      "to": 264,
      "from": "Bristol-Myers Squibb",
      "partnership": "Acquisition",
      "sector": "Drug discovery and Development",
      "modality": "Precision Therapeutics ",
      "companyName": "Turning Point Therapeutics",
      "marketValue": 4100
    },
    {
      "to": 265,
      "from": "Bristol-Myers Squibb",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "In-silico drug discovery",
      "companyName": "BigHat Biosciences",
      "marketValue": 75
    },
    {
      "to": 266,
      "from": "Bristol-Myers Squibb",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "AI in clinical trials",
      "companyName": "Owkin",
      "marketValue": 180
    },
    {
      "to": 267,
      "from": "Bristol-Myers Squibb",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "In-silico drug discovery",
      "companyName": "Transition Bio",
      "marketValue": 50
    },
    {
      "to": 268,
      "from": "Bristol-Myers Squibb",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Protein and peptide-based therapeutics",
      "companyName": "Sapience Therapeutics",
      "marketValue": 41
    },
    {
      "to": 269,
      "from": "Bristol-Myers Squibb",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Precision Therapeutics ",
      "companyName": "Nuvig Therapeutics",
      "marketValue": 47
    },
    {
      "to": 270,
      "from": "Bristol-Myers Squibb",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Precision Therapeutics ",
      "companyName": "Octant Bio",
      "marketValue": 80
    },
    {
      "to": 271,
      "from": "Bristol-Myers Squibb",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Engineered B Cell Medicines (BeCM)",
      "companyName": "Be Biopharma",
      "marketValue": 130
    },
    {
      "to": 272,
      "from": "Bristol-Myers Squibb",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "RNA Therapeutics",
      "companyName": "Ceptur Therapeutics",
      "marketValue": 75
    },
    {
      "to": 273,
      "from": "Bristol-Myers Squibb",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Precision Therapeutics ",
      "companyName": "Compugen",
      "marketValue": 20
    },
    {
      "to": 274,
      "from": "Bristol-Myers Squibb",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Targeted Protein Degradation",
      "companyName": "GlycoEra",
      "marketValue": "NA"
    },
    {
      "to": 275,
      "from": "Bristol-Myers Squibb",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Precision Therapeutics ",
      "companyName": "Nitrase Therapeutics",
      "marketValue": 45
    },
    {
      "to": 276,
      "from": "Bristol-Myers Squibb",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Cell therapy",
      "companyName": "Treefrog Therapeutics",
      "marketValue": 75
    },
    {
      "to": 277,
      "from": "Bristol-Myers Squibb",
      "partnership": "Partnership",
      "sector": "Drug discovery and Development",
      "modality": "Cell therapy",
      "companyName": "Obsidian Therapeutics",
      "marketValue": "NA"
    },
    {
      "to": 278,
      "from": "Bristol-Myers Squibb",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "RNA Therapeutics",
      "companyName": "Cardior",
      "marketValue": 76
    },
    {
      "to": 279,
      "from": "Bristol-Myers Squibb",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Precision Therapeutics ",
      "companyName": "IMIDomics",
      "marketValue": 16.5
    },
    {
      "to": 280,
      "from": "Bristol-Myers Squibb",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Neuroscience Therapy",
      "companyName": "Allyx Therapeutics",
      "marketValue": "NA"
    },
    {
      "to": 281,
      "from": "Bristol-Myers Squibb",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Precision Therapeutics ",
      "companyName": "HiberCell, Inc.",
      "marketValue": 67.4
    },
    {
      "to": 282,
      "from": "Bristol-Myers Squibb",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "In-silico drug discovery",
      "companyName": "Exscientia",
      "marketValue": 1375
    },
    {
      "to": 283,
      "from": "Bristol-Myers Squibb",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Gene therapy",
      "companyName": "Akamis Bio",
      "marketValue": "NA"
    },
    {
      "to": 284,
      "from": "Bristol-Myers Squibb",
      "partnership": "Acquisition",
      "sector": "Drug discovery and Development",
      "modality": "Precision Therapeutics ",
      "companyName": "MyoKardia",
      "marketValue": 13100
    },
    {
      "to": 285,
      "from": "Bristol-Myers Squibb",
      "partnership": "Acquisition",
      "sector": "Drug discovery and Development",
      "modality": "Precision Therapeutics ",
      "companyName": "Galecto",
      "marketValue": 64
    },
    {
      "to": 286,
      "from": "Bristol-Myers Squibb",
      "partnership": "Acquisition",
      "sector": "Drug discovery and Development",
      "modality": "Precision Therapeutics ",
      "companyName": "Forbius",
      "marketValue": "NA"
    },
    {
      "to": 287,
      "from": "Bristol-Myers Squibb",
      "partnership": "Investment",
      "sector": "Biotechnology ",
      "modality": "Digital health tool",
      "companyName": "SyncSense",
      "marketValue": "NA"
    },
    {
      "to": 288,
      "from": "Bristol-Myers Squibb",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Precision Therapeutics ",
      "companyName": "Repare Therapeutics",
      "marketValue": 65
    },
    {
      "to": 289,
      "from": "Bristol-Myers Squibb",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Antibody-Drug Conjugate (ADC)",
      "companyName": "Silverback Therapeutics",
      "marketValue": 78.5
    },
    {
      "to": 290,
      "from": "Bristol-Myers Squibb",
      "partnership": "Acquisition",
      "sector": "Drug discovery and Development",
      "modality": "Cell therapy",
      "companyName": "Celgene",
      "marketValue": 7400
    },
    {
      "to": 291,
      "from": "Bristol-Myers Squibb",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Precision Therapeutics ",
      "companyName": "Alpha Cancer Technologies",
      "marketValue": "NA"
    },
    {
      "to": 292,
      "from": "Bristol-Myers Squibb",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Microbiome-based therapies",
      "companyName": "Vedanta Biosciences ",
      "marketValue": 18.5
    },
    {
      "to": 293,
      "from": "Bristol-Myers Squibb",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Small molecule therapy",
      "companyName": "Ayala Pharmaceuticals",
      "marketValue": 17
    },
    {
      "to": 294,
      "from": "Bristol-Myers Squibb",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Microbiome-based therapies",
      "companyName": "Enterome",
      "marketValue": 38.5
    },
    {
      "to": 295,
      "from": "Bristol-Myers Squibb",
      "partnership": "Investment",
      "sector": "Biotechnology ",
      "modality": "in vitro diagnostic (IVD) genome testing",
      "companyName": "Personal Genome Diagnostics",
      "marketValue": 75
    },
    {
      "to": 296,
      "from": "Johnson & Johnson",
      "partnership": "Acquisition",
      "sector": "Drug discovery and Development",
      "modality": "Antibody-Drug Conjugate (ADC)",
      "companyName": "Ambrx",
      "marketValue": 2000
    },
    {
      "to": 297,
      "from": "Johnson & Johnson",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Neuroscience therapy",
      "companyName": "Arkuda Therapeutics",
      "marketValue": "NA"
    },
    {
      "to": 298,
      "from": "Johnson & Johnson",
      "partnership": "Investment",
      "sector": "Drug Delivery Technology",
      "modality": "Precision Therapeutics ",
      "companyName": "Elektrofi",
      "marketValue": 173
    },
    {
      "to": 299,
      "from": "Johnson & Johnson",
      "partnership": "Investment",
      "sector": "Disease Diagnostics and Devices",
      "modality": "Minimal residual disease (MRD) testing",
      "companyName": "Illumina Inc",
      "marketValue": "NA"
    },
    {
      "to": 300,
      "from": "Johnson & Johnson",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": " Nanotherapeutics",
      "companyName": "Nanobiotix",
      "marketValue": 1830
    },
    {
      "to": 301,
      "from": "Johnson & Johnson",
      "partnership": "Investment",
      "sector": "Disease Diagnostics and Devices",
      "modality": "Intraoperative molecular imaging",
      "companyName": "On Target Laboratories",
      "marketValue": 30
    },
    {
      "to": 302,
      "from": "Johnson & Johnson",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Protein and peptide-based Therapeutics",
      "companyName": "Aro Biotherapeutics",
      "marketValue": 41.5
    },
    {
      "to": 303,
      "from": "Johnson & Johnson",
      "partnership": "Partnership",
      "sector": "Drug discovery and Development",
      "modality": "In-silico drug discovery",
      "companyName": "Intelligent OMICS Ltd.",
      "marketValue": "NA"
    },
    {
      "to": 304,
      "from": "Johnson & Johnson",
      "partnership": "Partnership",
      "sector": "Drug discovery and Development",
      "modality": "Precision Therapeutics ",
      "companyName": "LAVA Therapeutics",
      "marketValue": "NA"
    },
    {
      "to": 305,
      "from": "Johnson & Johnson",
      "partnership": "Investment",
      "sector": "Drug manufacturing",
      "modality": " Automated drug manufacturing technology",
      "companyName": "Astraveus",
      "marketValue": 18.1
    },
    {
      "to": 306,
      "from": "Johnson & Johnson",
      "partnership": "Investment",
      "sector": "Medical Devices & Equipment",
      "modality": "Robotic surgery",
      "companyName": "Moon Surgical",
      "marketValue": 55.4
    },
    {
      "to": 307,
      "from": "Johnson & Johnson",
      "partnership": "Investment",
      "sector": "Disease Diagnostics and Devices",
      "modality": "Non-invasive healthcare devices",
      "companyName": "Solenic Medical ",
      "marketValue": 5.1
    },
    {
      "to": 308,
      "from": "Johnson & Johnson",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Cell therapy",
      "companyName": "ID Pharma",
      "marketValue": "NA"
    },
    {
      "to": 309,
      "from": "Johnson & Johnson",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Neuroscience therapy",
      "companyName": "Contineum Therapeutics\n(Before named as Pipeline therapeutics)",
      "marketValue": 1100
    },
    {
      "to": 310,
      "from": "Johnson & Johnson",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Neuroscience therapy",
      "companyName": "Rapport Therapeutics",
      "marketValue": 150
    },
    {
      "to": 311,
      "from": "Johnson & Johnson",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Precision Therapeutics ",
      "companyName": "Biocytogen Pharmaceuticals",
      "marketValue": "NA"
    },
    {
      "to": 312,
      "from": "Johnson & Johnson",
      "partnership": "Investment",
      "sector": "Disease Diagnostics and Devices",
      "modality": "AI-powered diagnostics",
      "companyName": "ArteraAI",
      "marketValue": 90
    },
    {
      "to": 313,
      "from": "Johnson & Johnson",
      "partnership": "Investment",
      "sector": "Disease Diagnostics and Devices",
      "modality": "Non-invasive healthcare devices",
      "companyName": "Prana Thoracic",
      "marketValue": 3
    },
    {
      "to": 314,
      "from": "Johnson & Johnson",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Gene therapy",
      "companyName": "MeiraGTx",
      "marketValue": 415
    },
    {
      "to": 315,
      "from": "Johnson & Johnson",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Antibody-Drug Conjugate (ADC)",
      "companyName": "LegoChem Biosciences",
      "marketValue": 1800
    },
    {
      "to": 316,
      "from": "Johnson & Johnson",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Antibody-Drug Conjugate (ADC)",
      "companyName": "Mersana Therapeutics",
      "marketValue": 1040
    },
    {
      "to": 317,
      "from": "Johnson & Johnson",
      "partnership": "Acquisition",
      "sector": "Biotechnology ",
      "modality": "Therapeutic devices",
      "companyName": "Abiomed",
      "marketValue": 16600
    },
    {
      "to": 318,
      "from": "Johnson & Johnson",
      "partnership": "Investment",
      "sector": "Medical Devices & Equipment",
      "modality": "Non-invasive healthcare devices",
      "companyName": "HistoSonics",
      "marketValue": 85
    },
    {
      "to": 319,
      "from": "Johnson & Johnson",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Precision Therapeutics ",
      "companyName": "Osteal Therapeutics",
      "marketValue": 30
    },
    {
      "to": 320,
      "from": "Johnson & Johnson",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Gene therapy",
      "companyName": "WuXi Advanced Therapies",
      "marketValue": "NA"
    },
    {
      "to": 321,
      "from": "Johnson & Johnson",
      "partnership": "Partnership",
      "sector": "Disease Diagnostics and Devices",
      "modality": "AI-powered diagnostics",
      "companyName": "Paige",
      "marketValue": "NA"
    },
    {
      "to": 322,
      "from": "Johnson & Johnson",
      "partnership": "Partnership",
      "sector": "Drug discovery and Development",
      "modality": "Cell therapy",
      "companyName": "Serotiny",
      "marketValue": "NA"
    },
    {
      "to": 323,
      "from": "Johnson & Johnson",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Antibody-Drug Conjugate (ADC)",
      "companyName": "Hangzhou DAC Biotechnology",
      "marketValue": "NA"
    },
    {
      "to": 324,
      "from": "Johnson & Johnson",
      "partnership": "Investment",
      "sector": "Biotechnology ",
      "modality": "Gene editing technologies (CRISPR)",
      "companyName": "Locus Biosciences",
      "marketValue": 35
    },
    {
      "to": 325,
      "from": "Johnson & Johnson",
      "partnership": "Partnership",
      "sector": "Drug discovery and Development",
      "modality": "In-silico drug discovery",
      "companyName": "VantAI",
      "marketValue": "NA"
    },
    {
      "to": 326,
      "from": "Johnson & Johnson",
      "partnership": "Partnership",
      "sector": "Drug Delivery Technology",
      "modality": " Neuroscience Therapy",
      "companyName": "Bioasis Technologies",
      "marketValue": "NA"
    },
    {
      "to": 327,
      "from": "Johnson & Johnson",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Bispecific antibodies",
      "companyName": "Rondo Therapeutics",
      "marketValue": 67
    },
    {
      "to": 328,
      "from": "Johnson & Johnson",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Small molecule therapy",
      "companyName": "Remix Therapeutics",
      "marketValue": 1045
    },
    {
      "to": 329,
      "from": "Johnson & Johnson",
      "partnership": "Partnership",
      "sector": "Drug discovery and Development",
      "modality": "Precision Therapeutics ",
      "companyName": "VerImmune",
      "marketValue": "NA"
    },
    {
      "to": 330,
      "from": "Johnson & Johnson",
      "partnership": "Acquisition",
      "sector": "Drug discovery and Development",
      "modality": "Precision Therapeutics ",
      "companyName": "Anakuria Therapeutics",
      "marketValue": "NA"
    },
    {
      "to": 331,
      "from": "Johnson & Johnson",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "AI in clinical trials",
      "companyName": "Iterative Scopes ",
      "marketValue": 150
    },
    {
      "to": 332,
      "from": "Johnson & Johnson",
      "partnership": "Partnership",
      "sector": "Drug Delivery Technology",
      "modality": "Intranasal spray medications ",
      "companyName": "Leyden Labs",
      "marketValue": "NA"
    },
    {
      "to": 333,
      "from": "Johnson & Johnson",
      "partnership": "Partnership",
      "sector": "Drug Delivery Technology",
      "modality": "Ionic liquid technology",
      "companyName": "i2o Therapeutics",
      "marketValue": "NA"
    },
    {
      "to": 334,
      "from": "Johnson & Johnson",
      "partnership": "Partnership",
      "sector": "Drug discovery and Development",
      "modality": "Small molecule therapy",
      "companyName": "SRI International",
      "marketValue": "NA"
    },
    {
      "to": 335,
      "from": "Johnson & Johnson",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Precision Therapeutics ",
      "companyName": "TRexBio",
      "marketValue": 59
    },
    {
      "to": 336,
      "from": "Johnson & Johnson",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "AI in clinical trials",
      "companyName": "Verana Health",
      "marketValue": 150
    },
    {
      "to": 337,
      "from": "Johnson & Johnson",
      "partnership": "Acquisition",
      "sector": "Biotechnology ",
      "modality": "Therapeutic devices",
      "companyName": "CrossRoads Extremity Systems",
      "marketValue": "NA"
    },
    {
      "to": 338,
      "from": "Johnson & Johnson",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Neuroscience therapy",
      "companyName": "AviadoBio",
      "marketValue": 80
    },
    {
      "to": 339,
      "from": "Johnson & Johnson",
      "partnership": "Partnership",
      "sector": "Drug discovery and Development",
      "modality": "Small molecule therapy",
      "companyName": "Philogen ",
      "marketValue": "NA"
    },
    {
      "to": 340,
      "from": "Johnson & Johnson",
      "partnership": "Partnership",
      "sector": "Healthcare SaaS",
      "modality": "AI-powered diagnostics",
      "companyName": "Ultromics",
      "marketValue": "NA"
    },
    {
      "to": 341,
      "from": "Johnson & Johnson",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Active pharmaceutical ingredients (APIs)",
      "companyName": "entrinsic bioscience",
      "marketValue": 49
    },
    {
      "to": 342,
      "from": "Johnson & Johnson",
      "partnership": "Investment",
      "sector": "Biotechnology",
      "modality": "Digital health tool",
      "companyName": "Thirty Madison",
      "marketValue": 140
    },
    {
      "to": 343,
      "from": "Johnson & Johnson",
      "partnership": "Investment",
      "sector": "Disease Diagnostics and Devices",
      "modality": "Digital health tool",
      "companyName": "Cue Health",
      "marketValue": 235
    },
    {
      "to": 344,
      "from": "Johnson & Johnson",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Antiviral Conjugates (AVCs)",
      "companyName": "Cidara Therapeutics",
      "marketValue": 780
    },
    {
      "to": 345,
      "from": "Johnson & Johnson",
      "partnership": "Investment",
      "sector": "Healthcare SaaS",
      "modality": "AI-powered diagnostics",
      "companyName": "Techsomed",
      "marketValue": 7
    },
    {
      "to": 346,
      "from": "Johnson & Johnson",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Microbiome-based therapies",
      "companyName": "Evolve BioSystems",
      "marketValue": 55
    },
    {
      "to": 347,
      "from": "Johnson & Johnson",
      "partnership": "Partnership",
      "sector": "Drug discovery and Development",
      "modality": "Precision Therapeutics ",
      "companyName": "Morphic Therapeutic",
      "marketValue": "NA"
    },
    {
      "to": 348,
      "from": "Johnson & Johnson",
      "partnership": "Partnership",
      "sector": "Drug discovery and Development",
      "modality": "Bispecific antibodies",
      "companyName": "Revitope Oncology ",
      "marketValue": "NA"
    },
    {
      "to": 349,
      "from": "Johnson & Johnson",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Bispecific antibodies",
      "companyName": "Xencor",
      "marketValue": 1313
    },
    {
      "to": 350,
      "from": "Johnson & Johnson",
      "partnership": "Partnership",
      "sector": "Drug discovery and Development",
      "modality": "Microbiome-based therapies",
      "companyName": "Persephone Biosciences",
      "marketValue": "NA"
    },
    {
      "to": 351,
      "from": "Johnson & Johnson",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Precision Therapeutics ",
      "companyName": "Mestag Therapeutics ",
      "marketValue": 45
    },
    {
      "to": 352,
      "from": "Johnson & Johnson",
      "partnership": "Acquisition",
      "sector": "Medical Devices & Equipment",
      "modality": "Therapeutic devices",
      "companyName": "OrthoSpin ",
      "marketValue": "NA"
    },
    {
      "to": 353,
      "from": "Johnson & Johnson",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Precision Therapeutics ",
      "companyName": "ONL Therapeutics",
      "marketValue": 61.9
    },
    {
      "to": 354,
      "from": "Johnson & Johnson",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Precision Therapeutics ",
      "companyName": "MacroGenics",
      "marketValue": 332
    },
    {
      "to": 355,
      "from": "Johnson & Johnson",
      "partnership": "Partnership",
      "sector": "Drug manufacturing",
      "modality": "Protein and peptide-based therapeutics",
      "companyName": "CHO Plus",
      "marketValue": "NA"
    },
    {
      "to": 356,
      "from": "Johnson & Johnson",
      "partnership": "Partnership",
      "sector": "Drug discovery and Development",
      "modality": "Precision Therapeutics ",
      "companyName": "Symvivo Corporation",
      "marketValue": "NA"
    },
    {
      "to": 357,
      "from": "Johnson & Johnson",
      "partnership": "Investment",
      "sector": "Healthcare SaaS",
      "modality": "Digital health tool",
      "companyName": "Koa Health",
      "marketValue": "NA"
    },
    {
      "to": 358,
      "from": "Johnson & Johnson",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Cell therapy",
      "companyName": "ImmPACT Bio",
      "marketValue": 18
    },
    {
      "to": 359,
      "from": "Johnson & Johnson",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Microbiome-based therapies",
      "companyName": "Dermala",
      "marketValue": 6.73
    },
    {
      "to": 360,
      "from": "Johnson & Johnson",
      "partnership": "Investment",
      "sector": "Healthcare SaaS",
      "modality": "Digital health tool",
      "companyName": "Datavant",
      "marketValue": 40
    },
    {
      "to": 361,
      "from": "Johnson & Johnson",
      "partnership": "Investment",
      "sector": "Medical Devices & Equipment",
      "modality": "Therapeutic devices",
      "companyName": "V-Wave",
      "marketValue": 98
    },
    {
      "to": 362,
      "from": "Johnson & Johnson",
      "partnership": "Investment",
      "sector": "Medical Devices & Equipment",
      "modality": "Therapeutic devices",
      "companyName": "GI Windows Medical Corp",
      "marketValue": 16.4
    },
    {
      "to": 363,
      "from": "Johnson & Johnson",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Neuroscience therapy",
      "companyName": "XWPharma",
      "marketValue": 40
    },
    {
      "to": 364,
      "from": "Johnson & Johnson",
      "partnership": "Investment",
      "sector": "Healthcare SaaS",
      "modality": "Digital health tool",
      "companyName": "Aetion",
      "marketValue": 19
    },
    {
      "to": 365,
      "from": "Johnson & Johnson",
      "partnership": "Partnership",
      "sector": "Drug discovery and Development",
      "modality": "In-silico drug discovery",
      "companyName": "Envisagenics",
      "marketValue": "NA"
    },
    {
      "to": 366,
      "from": "Johnson & Johnson",
      "partnership": "Investment",
      "sector": "Medical Devices & Equipment",
      "modality": "Radiopharmaceutical therapy",
      "companyName": "RefleXion",
      "marketValue": 100
    },
    {
      "to": 367,
      "from": "Johnson & Johnson",
      "partnership": "Partnership",
      "sector": "Drug discovery and Development",
      "modality": "RNA Therapeutics",
      "companyName": "Exonate",
      "marketValue": "NA"
    },
    {
      "to": 368,
      "from": "Johnson & Johnson",
      "partnership": "Investment",
      "sector": "Healthcare SaaS",
      "modality": "Digital health tool",
      "companyName": "ConcertAI",
      "marketValue": "NA"
    },
    {
      "to": 369,
      "from": "Johnson & Johnson",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Cell therapy",
      "companyName": "Vor Biopharma",
      "marketValue": 110
    },
    {
      "to": 370,
      "from": "Johnson & Johnson",
      "partnership": "Investment",
      "sector": "Medical Devices & Equipment",
      "modality": " Implantable medical device",
      "companyName": "CVRx®",
      "marketValue": 50
    },
    {
      "to": 371,
      "from": "Johnson & Johnson",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Gene therapy",
      "companyName": "Hemera Biosciences ",
      "marketValue": "NA"
    },
    {
      "to": 372,
      "from": "Johnson & Johnson",
      "partnership": "Acquisition",
      "sector": "Drug discovery and Development",
      "modality": "Precision Therapeutics ",
      "companyName": "Momenta Pharmaceuticals",
      "marketValue": 6500
    },
    {
      "to": 373,
      "from": "Johnson & Johnson",
      "partnership": "Acquisition",
      "sector": "Biotechnology ",
      "modality": "Therapeutic devices",
      "companyName": "Verb Surgical",
      "marketValue": "NA"
    },
    {
      "to": 374,
      "from": "Johnson & Johnson",
      "partnership": "Acquisition",
      "sector": "Drug Delivery Technology",
      "modality": "Precision Therapeutics ",
      "companyName": "Taris Biomedical",
      "marketValue": "NA"
    },
    {
      "to": 375,
      "from": "Johnson & Johnson",
      "partnership": "Acquisition",
      "sector": "Biotechnology ",
      "modality": "Robotic surgery",
      "companyName": "Auris",
      "marketValue": 5750
    },
    {
      "to": 376,
      "from": "Johnson & Johnson",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Microbiome-based therapies",
      "companyName": "Holobiome",
      "marketValue": "NA"
    },
    {
      "to": 377,
      "from": "Johnson & Johnson",
      "partnership": "Acquisition",
      "sector": "Biotechnology ",
      "modality": "Therapeutic devices",
      "companyName": "Emerging Implant Technologies (EIT)",
      "marketValue": "NA"
    },
    {
      "to": 378,
      "from": "Johnson & Johnson",
      "partnership": "Acquisition",
      "sector": "Biotechnology ",
      "modality": "Robotic surgery",
      "companyName": "Orthotaxy",
      "marketValue": "NA"
    },
    {
      "to": 379,
      "from": "Pfizer",
      "partnership": "Acquisition",
      "sector": "Drug discovery and Development",
      "modality": "Precision Therapeutics ",
      "companyName": "Biohaven Pharmaceutical Holding Company Ltd.",
      "marketValue": 11600
    },
    {
      "to": 380,
      "from": "Pfizer",
      "partnership": "Acquisition",
      "sector": "Drug discovery and Development",
      "modality": "Antibody-Drug Conjugate (ADC)",
      "companyName": "Seagen",
      "marketValue": 43000
    },
    {
      "to": 381,
      "from": "Pfizer",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Vaccines",
      "companyName": "BioNTech",
      "marketValue": 748
    },
    {
      "to": 382,
      "from": "Pfizer",
      "partnership": "Investment",
      "sector": "Drug discovery and development",
      "modality": "Cell therapy",
      "companyName": "Caribou Biosciences",
      "marketValue": 25
    },
    {
      "to": 383,
      "from": "Pfizer",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Cell therapy",
      "companyName": "Caribou Biosciences",
      "marketValue": 25
    },
    {
      "to": 384,
      "from": "Pfizer",
      "partnership": "Investment",
      "sector": "Biotechnology",
      "modality": "Gene editing (ZFP)",
      "companyName": "Sangamo Therapeutics",
      "marketValue": 167
    },
    {
      "to": 385,
      "from": "Pfizer",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Gene therapy",
      "companyName": "Homology Medicines, Inc.",
      "marketValue": 60
    },
    {
      "to": 386,
      "from": "Pfizer",
      "partnership": "Investment",
      "sector": "Biotechnology",
      "modality": "Gene editing technologies (CRISPR)",
      "companyName": "Beam Therapeutics Inc.",
      "marketValue": 1350
    },
    {
      "to": 387,
      "from": "Pfizer",
      "partnership": "Investment",
      "sector": "Biotechnology",
      "modality": "In-silico drug discovery",
      "companyName": "CytoReason",
      "marketValue": 110
    },
    {
      "to": 388,
      "from": "Pfizer",
      "partnership": "Acquisition",
      "sector": "Drug discovery and Development",
      "modality": "Small molecule therapy",
      "companyName": "Global Blood Therapeutics",
      "marketValue": 5400
    },
    {
      "to": 389,
      "from": "Pfizer",
      "partnership": "Investment",
      "sector": "Biotechnology",
      "modality": "In-silico drug discovery",
      "companyName": "Gero.AI",
      "marketValue": "NA"
    },
    {
      "to": 390,
      "from": "Pfizer",
      "partnership": "Investment",
      "sector": "Biotechnology",
      "modality": "In-silico drug discovery",
      "companyName": "PostEra",
      "marketValue": 261
    },
    {
      "to": 391,
      "from": "Pfizer",
      "partnership": "Partnership",
      "sector": "Drug discovery and Development",
      "modality": "AI in clinical trials",
      "companyName": "Tempus",
      "marketValue": "NA"
    },
    {
      "to": 392,
      "from": "Pfizer",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Small molecule therapy",
      "companyName": "Spero Therapeutics",
      "marketValue": 120
    },
    {
      "to": 393,
      "from": "Pfizer",
      "partnership": "Investment",
      "sector": "Biotechnology",
      "modality": "RNA Therapeutics",
      "companyName": "Ginkgo Bioworks",
      "marketValue": 331
    },
    {
      "to": 394,
      "from": "Pfizer",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Small molecule therapy",
      "companyName": "CellCentric",
      "marketValue": 25
    },
    {
      "to": 395,
      "from": "Pfizer",
      "partnership": "Acquisition",
      "sector": "Drug discovery and Development",
      "modality": "Protein and peptide-based therapeutics",
      "companyName": "Therachon Holding AG",
      "marketValue": 810
    },
    {
      "to": 396,
      "from": "Pfizer",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Microbiome-based therapies",
      "companyName": "Vedanta Biosciences",
      "marketValue": 25
    },
    {
      "to": 397,
      "from": "Pfizer",
      "partnership": "Investment",
      "sector": "Biotechnology",
      "modality": "In-silico drug discovery",
      "companyName": "Herophilus (Formely System1 Biosciences)",
      "marketValue": 25
    },
    {
      "to": 398,
      "from": "Pfizer",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "RNA Therapeutics",
      "companyName": "Voyager Therapeutics",
      "marketValue": 630
    },
    {
      "to": 399,
      "from": "Pfizer",
      "partnership": "Acquisition",
      "sector": "Drug discovery and Development",
      "modality": "Small molecule therapy",
      "companyName": "Array BioPharma",
      "marketValue": 11400
    },
    {
      "to": 400,
      "from": "Pfizer",
      "partnership": "Partnership",
      "sector": "Drug manufacturing",
      "modality": "Small molecule therapy",
      "companyName": "CSPC Pharmaceutical Group",
      "marketValue": "NA"
    },
    {
      "to": 401,
      "from": "Pfizer",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Small molecule therapy",
      "companyName": "Ribon Therapeutics",
      "marketValue": 25
    },
    {
      "to": 402,
      "from": "Pfizer",
      "partnership": "Partnership",
      "sector": "Biotechnology",
      "modality": "In-silico drug discovery",
      "companyName": "XtalPi Inc.",
      "marketValue": "NA"
    },
    {
      "to": 403,
      "from": "Pfizer",
      "partnership": "Partnership",
      "sector": "Biotechnology",
      "modality": "In-silico drug discovery",
      "companyName": "Insilico Medicine",
      "marketValue": "NA"
    },
    {
      "to": 404,
      "from": "Pfizer",
      "partnership": "Partnership",
      "sector": "Biotechnology",
      "modality": "In-silico drug discovery",
      "companyName": "Iktos",
      "marketValue": "NA"
    },
    {
      "to": 405,
      "from": "Pfizer",
      "partnership": "Partnership",
      "sector": "Drug Delivery Technology",
      "modality": "Polymer technology",
      "companyName": "Serina Therapeutics, Inc.",
      "marketValue": "NA"
    },
    {
      "to": 406,
      "from": "Pfizer",
      "partnership": "Partnership",
      "sector": "Healthcare SaaS",
      "modality": "Digital health tool",
      "companyName": "Ada Health",
      "marketValue": "NA"
    },
    {
      "to": 407,
      "from": "Pfizer",
      "partnership": "Partnership",
      "sector": "Healthcare SaaS",
      "modality": "Digital health tool",
      "companyName": "Cue Health",
      "marketValue": "NA"
    },
    {
      "to": 408,
      "from": "Pfizer",
      "partnership": "Acquisition",
      "sector": "Disease Diagnostics and Devices",
      "modality": "Non-invasive healthcare devices",
      "companyName": "Lucira Health",
      "marketValue": 36.4
    },
    {
      "to": 409,
      "from": "Pfizer",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Small molecule therapy",
      "companyName": "ORIC Pharmaceuticals",
      "marketValue": 25
    },
    {
      "to": 410,
      "from": "Pfizer",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Small molecule therapy",
      "companyName": "Carrick Therapeutics",
      "marketValue": 35
    },
    {
      "to": 411,
      "from": "Pfizer",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Precision Therapeutics ",
      "companyName": "Anokion",
      "marketValue": 35
    },
    {
      "to": 412,
      "from": "Pfizer",
      "partnership": "Acquisition",
      "sector": "Disease Diagnostics and Devices",
      "modality": "Digital health tool",
      "companyName": "ResApp Health",
      "marketValue": 116
    },
    {
      "to": 413,
      "from": "Pfizer",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Small molecule therapy",
      "companyName": "AgomAb Therapeutics",
      "marketValue": 40.5
    },
    {
      "to": 414,
      "from": "Pfizer",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Vaccines",
      "companyName": "Valneva",
      "marketValue": 95
    },
    {
      "to": 415,
      "from": "Pfizer",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Protein and peptide-based therapeutics",
      "companyName": "Akero Therapeutics",
      "marketValue": 25
    },
    {
      "to": 416,
      "from": "Pfizer",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Bispecific antibodies",
      "companyName": "Dren Bio",
      "marketValue": 1025
    },
    {
      "to": 417,
      "from": "Pfizer",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Small molecule therapy",
      "companyName": "Zentalis Pharmaceuticals",
      "marketValue": 25
    },
    {
      "to": 418,
      "from": "Pfizer",
      "partnership": "Acquisition",
      "sector": "Drug discovery and Development",
      "modality": "Small molecule therapy",
      "companyName": "ReViral",
      "marketValue": 525
    },
    {
      "to": 419,
      "from": "Pfizer",
      "partnership": "Acquisition",
      "sector": "Drug discovery and Development",
      "modality": "Small molecule therapy",
      "companyName": "Arena Pharmaceuticals",
      "marketValue": 6700
    },
    {
      "to": 420,
      "from": "Pfizer",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Precision Therapeutics ",
      "companyName": "Cardiff Oncology",
      "marketValue": 15
    },
    {
      "to": 421,
      "from": "Pfizer",
      "partnership": "Acquisition",
      "sector": "Drug discovery and Development",
      "modality": "Protein and peptide-based therapeutics",
      "companyName": "Trillium Therapeutics",
      "marketValue": 2220
    },
    {
      "to": 422,
      "from": "Pfizer",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Targeted Protein Degradation",
      "companyName": "Arvinas",
      "marketValue": 2050
    },
    {
      "to": 423,
      "from": "Pfizer",
      "partnership": "Acquisition",
      "sector": "Drug discovery and Development",
      "modality": "Precision Therapeutics ",
      "companyName": "Amplyx Pharmaceuticals",
      "marketValue": "NA"
    },
    {
      "to": 424,
      "from": "Pfizer",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Protein and peptide-based therapeutics",
      "companyName": "ImCyse",
      "marketValue": 25.8
    },
    {
      "to": 425,
      "from": "Pfizer",
      "partnership": "Investment",
      "sector": "Drug manufacturing",
      "modality": "Small molecule therapy",
      "companyName": "LianBio",
      "marketValue": 155
    },
    {
      "to": 426,
      "from": "Pfizer",
      "partnership": "Acquisition",
      "sector": "Drug discovery and Development",
      "modality": "Small molecule therapy",
      "companyName": "Arixa Pharmaceuticals",
      "marketValue": "NA"
    },
    {
      "to": 427,
      "from": "Pfizer",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Antibody-Drug Conjugate (ADC)",
      "companyName": "CStone Pharmaceuticals",
      "marketValue": 200
    },
    {
      "to": 428,
      "from": "Pfizer",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Direct Lytic Agents (DLAs)",
      "companyName": "ContraFect",
      "marketValue": 3
    },
    {
      "to": 429,
      "from": "Pfizer",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Gene therapy",
      "companyName": "Vivet Therapeutics",
      "marketValue": 651
    },
    {
      "to": 430,
      "from": "Pfizer",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Protein and peptide-based therapeutics",
      "companyName": "Gliknik",
      "marketValue": 15
    },
    {
      "to": 431,
      "from": "Pfizer",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Antibody-Drug Conjugate (ADC)",
      "companyName": "Nona Biosciences",
      "marketValue": 1103
    },
    {
      "to": 432,
      "from": "Pfizer",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Vaccines",
      "companyName": "BioNTech",
      "marketValue": 425
    },
    {
      "to": 433,
      "from": "Pfizer",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Protein and peptide-based therapeutics",
      "companyName": "ImmunOs Therapeutics AG",
      "marketValue": 16.9
    },
    {
      "to": 434,
      "from": "Pfizer",
      "partnership": "Partnership",
      "sector": "Healthcare SaaS",
      "modality": "Digital health tool",
      "companyName": "Truveta",
      "marketValue": "NA"
    },
    {
      "to": 435,
      "from": "Pfizer",
      "partnership": "Partnership",
      "sector": "Healthcare SaaS",
      "modality": "Digital health tool",
      "companyName": "Ranok Therapeutics",
      "marketValue": "NA"
    },
    {
      "to": 436,
      "from": "Pfizer",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Multiple modalities",
      "companyName": "Anjarium Biosciences",
      "marketValue": 61
    },
    {
      "to": 437,
      "from": "Pfizer",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Protein and peptide-based therapeutics",
      "companyName": "Mediar Therapeutics",
      "marketValue": "NA"
    },
    {
      "to": 438,
      "from": "Pfizer",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "RNA Therapeutics",
      "companyName": "Telesis Bio, Inc. (Formely Codex DNA)",
      "marketValue": 100
    },
    {
      "to": 439,
      "from": "Pfizer",
      "partnership": "Partnership",
      "sector": "Drug discovery and Development",
      "modality": "Multiple modalities",
      "companyName": "SpringWorks Therapeutics",
      "marketValue": "NA"
    },
    {
      "to": 440,
      "from": "Pfizer",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Precision Therapeutics ",
      "companyName": "Montis Biosciences",
      "marketValue": 9.02
    },
    {
      "to": 441,
      "from": "Bayer",
      "partnership": "Acquisition",
      "sector": "Drug discovery and development",
      "modality": "Cell therapy",
      "companyName": "BlueRock Therapeutics",
      "marketValue": 250
    },
    {
      "to": 442,
      "from": "Bayer",
      "partnership": "Acquisition",
      "sector": "Drug discovery and development",
      "modality": "Gene therapy",
      "companyName": "Asklepios BioPharmaceutical",
      "marketValue": 4000
    },
    {
      "to": 443,
      "from": "Bayer",
      "partnership": "Partnership",
      "sector": "Drug Delivery Technology",
      "modality": "Gene therapy",
      "companyName": "Acuitas Therapeutics, Inc.",
      "marketValue": "NA"
    },
    {
      "to": 444,
      "from": "Bayer",
      "partnership": "Investment",
      "sector": "Drug discovery and development",
      "modality": "Gene circuit-engineered cell and gene therapies",
      "companyName": "Senti Biosciences, Inc.",
      "marketValue": 105
    },
    {
      "to": 445,
      "from": "Bayer",
      "partnership": "Investment",
      "sector": "Drug discovery and development",
      "modality": "Cell therapy",
      "companyName": "Triumvira Immunologics Inc",
      "marketValue": 100
    },
    {
      "to": 446,
      "from": "Bayer",
      "partnership": "Acquisition",
      "sector": "Drug discovery and development",
      "modality": "Targeted Alpha Therapies (TATs)",
      "companyName": "Noria Therapeutics",
      "marketValue": "NA"
    },
    {
      "to": 447,
      "from": "Bayer",
      "partnership": "Acquisition",
      "sector": "Drug discovery and development",
      "modality": "Drug development in Women’s Healthcare",
      "companyName": " KaNDy Therapeutics Ltd",
      "marketValue": 875
    },
    {
      "to": 448,
      "from": "Bayer",
      "partnership": "Investment",
      "sector": "Drug discovery and development",
      "modality": "Drug development in Women’s Healthcare",
      "companyName": "Systems Oncology",
      "marketValue": 345
    },
    {
      "to": 449,
      "from": "Bayer",
      "partnership": "Partnership",
      "sector": "Drug discovery and development",
      "modality": "Gene editing technologies (CRISPR)",
      "companyName": "Casebia Therapeutics (CRISPR Therapeutics and Bayer joint venture)",
      "marketValue": "NA"
    },
    {
      "to": 450,
      "from": "Bayer",
      "partnership": "Investment",
      "sector": "Drug discovery and development",
      "modality": "Gene editing technologies (CRISPR)",
      "companyName": "Metagenomi Technologies",
      "marketValue": 65
    },
    {
      "to": 451,
      "from": "Bayer",
      "partnership": "Investment",
      "sector": "Biotechnology",
      "modality": "Digital health tool",
      "companyName": "Huma Therapeutics ",
      "marketValue": 130
    },
    {
      "to": 452,
      "from": "Bayer",
      "partnership": "Investment",
      "sector": "Biotechnology",
      "modality": "Digital health tool",
      "companyName": "Ada Health",
      "marketValue": 90
    },
    {
      "to": 453,
      "from": "Bayer",
      "partnership": "Investment",
      "sector": "Biotechnology",
      "modality": "Digital health tool",
      "companyName": "One Drop",
      "marketValue": 100
    },
    {
      "to": 454,
      "from": "Bayer",
      "partnership": "Investment",
      "sector": "Drug Delivery Technology",
      "modality": "Gene editing technologies (CRISPR)",
      "companyName": "Vesigen Therapeutics",
      "marketValue": 28.5
    },
    {
      "to": 455,
      "from": "Bayer",
      "partnership": "Investment",
      "sector": "Biotechnology",
      "modality": "Microbiome-based therapies",
      "companyName": "Azitra Inc.",
      "marketValue": 17
    },
    {
      "to": 456,
      "from": "Bayer",
      "partnership": "Investment",
      "sector": "Drug discovery and Development",
      "modality": "Microbiome-based therapies",
      "companyName": "Bloom Science",
      "marketValue": 12
    },
    {
      "to": 457,
      "from": "Bayer",
      "partnership": "Investment",
      "sector": "Biotechnology",
      "modality": "Digital health tool",
      "companyName": "Elly Health",
      "marketValue": 1.3
    },
    {
      "to": 458,
      "from": "Bayer",
      "partnership": "Investment",
      "sector": "Biotechnology",
      "modality": "Digital health tool",
      "companyName": "Wellthy Therapeutics",
      "marketValue": "NA"
    },
    {
      "to": 459,
      "from": "Bayer",
      "partnership": "Investment",
      "sector": "Biotechnology",
      "modality": "Digital health tool",
      "companyName": "Visotec GmbH",
      "marketValue": 0.081
    },
    {
      "to": 460,
      "from": "Bayer",
      "partnership": "Investment",
      "sector": "Biotechnology",
      "modality": "Digital health tool",
      "companyName": "Upside Health",
      "marketValue": 0.2
    },
    {
      "to": 461,
      "from": "Bayer",
      "partnership": "Investment",
      "sector": "Drug discovery and development",
      "modality": "Gene therapy",
      "companyName": "Boundless Bio",
      "marketValue": 100
    },
    {
      "to": 462,
      "from": "Bayer",
      "partnership": "Investment",
      "sector": "Drug discovery and development",
      "modality": "Genomics analysis",
      "companyName": "Paratus Sciences",
      "marketValue": 100
    },
    {
      "to": 463,
      "from": "Bayer",
      "partnership": "Investment",
      "sector": "Biotechnology",
      "modality": "Digital health tool",
      "companyName": "Aparito",
      "marketValue": 1.1
    },
    {
      "to": 464,
      "from": "Bayer",
      "partnership": "Investment",
      "sector": "Biotechnology",
      "modality": "Digital health tool",
      "companyName": "Agamon Health",
      "marketValue": 3
    },
    {
      "to": 465,
      "from": "Bayer",
      "partnership": "Investment",
      "sector": "Drug Delivery Technology",
      "modality": "Gene therapy",
      "companyName": "Recode Therapeutics",
      "marketValue": 120
    },
    {
      "to": 466,
      "from": "Bayer",
      "partnership": "Investment",
      "sector": "Drug discovery and development",
      "modality": "Cell therapy",
      "companyName": "Affini-T Therapeutics ",
      "marketValue": 175
    },
    {
      "to": 467,
      "from": "Bayer",
      "partnership": "Investment",
      "sector": "Drug discovery and development",
      "modality": "Cell therapy",
      "companyName": "Indapta Therapeutics ",
      "marketValue": 50
    },
    {
      "to": 468,
      "from": "Bayer",
      "partnership": "Investment",
      "sector": "Biotechnology",
      "modality": "Digital health tool",
      "companyName": "Woebot Health",
      "marketValue": 9.5
    },
    {
      "to": 469,
      "from": "Bayer",
      "partnership": "Investment",
      "sector": "Drug manufacturing",
      "modality": "Cell therapy",
      "companyName": "Cellino",
      "marketValue": 80
    },
    {
      "to": 470,
      "from": "Bayer",
      "partnership": "Investment",
      "sector": "Drug discovery and development",
      "modality": "Protein and peptide-based Therapeutics",
      "companyName": "Deka Biosciences",
      "marketValue": 20
    },
    {
      "to": 471,
      "from": "Bayer",
      "partnership": "Investment",
      "sector": "Drug discovery and development",
      "modality": "Protein and peptide-based Therapeutics",
      "companyName": "GRO Biosciences Inc.",
      "marketValue": 25
    },
    {
      "to": 472,
      "from": "Bayer",
      "partnership": "Investment",
      "sector": "Drug discovery and development",
      "modality": "Precision Therapeutics ",
      "companyName": "Gandeeva Therapeutics",
      "marketValue": 40
    },
    {
      "to": 473,
      "from": "Bayer",
      "partnership": "Investment",
      "sector": "Drug discovery and development",
      "modality": "Cell therapy",
      "companyName": "Mozart Therapeutics",
      "marketValue": 55
    },
    {
      "to": 474,
      "from": "Bayer",
      "partnership": "Investment",
      "sector": "Biotechnology",
      "modality": "Digital health tool",
      "companyName": "Edifice Health ",
      "marketValue": 12
    },
    {
      "to": 475,
      "from": "Bayer",
      "partnership": "Investment",
      "sector": "Immunotherapy",
      "modality": "Therapeutics for Food allergy",
      "companyName": "Ukko",
      "marketValue": 40
    },
    {
      "to": 476,
      "from": "Bayer",
      "partnership": "Investment",
      "sector": "Drug discovery and development",
      "modality": "Precision Therapeutics ",
      "companyName": "Ji Xing Pharmaceuticals",
      "marketValue": 35
    },
    {
      "to": 477,
      "from": "Bayer",
      "partnership": "Acquisition",
      "sector": "Drug discovery and development",
      "modality": "Precision Therapeutics ",
      "companyName": "Vividion Therapeutics",
      "marketValue": 2000
    },
    {
      "to": 478,
      "from": "Bayer",
      "partnership": "Investment",
      "sector": "Drug discovery and development",
      "modality": "Radiopharmaceutical therapy",
      "companyName": "Ratio Therapeutics",
      "marketValue": 20
    },
    {
      "to": 479,
      "from": "Bayer",
      "partnership": "Investment",
      "sector": "Drug discovery and development",
      "modality": "Precision Therapeutics ",
      "companyName": "Recursion",
      "marketValue": 50
    },
    {
      "to": 480,
      "from": "Bayer",
      "partnership": "Investment",
      "sector": "Disease Diagnostics and Devices",
      "modality": "Non-invasive healthcare devices",
      "companyName": "Acorai\n",
      "marketValue": "NA"
    },
    {
      "to": 481,
      "from": "Bayer",
      "partnership": "Investment",
      "sector": "Drug discovery and development",
      "modality": "Vaccines",
      "companyName": "Khloris Biosciences",
      "marketValue": "NA"
    },
    {
      "to": 482,
      "from": "Bayer",
      "partnership": "Investment",
      "sector": "Drug discovery and development",
      "modality": "In-silico drug discovery",
      "companyName": "Dewpoint Therapeutics",
      "marketValue": 100
    },
    {
      "to": 483,
      "from": "Bayer",
      "partnership": "Investment",
      "sector": "Drug discovery and development",
      "modality": "Precision Therapeutics ",
      "companyName": "Pyxis Oncology",
      "marketValue": 22
    },
    {
      "to": 484,
      "from": "Bayer",
      "partnership": "Investment",
      "sector": "Drug discovery and development",
      "modality": "Cell therapy",
      "companyName": "Century Therapeutics",
      "marketValue": 250
    },
    {
      "to": 485,
      "from": "Bayer",
      "partnership": "Investment",
      "sector": "Organ Transplantation",
      "modality": "Gene editing technologies (CRISPR)",
      "companyName": "eGenesis",
      "marketValue": 50
    },
    {
      "to": 486,
      "from": "Bayer",
      "partnership": "Investment",
      "sector": "Drug discovery and development",
      "modality": "In-silico drug discovery",
      "companyName": "Kojin Therapeutics",
      "marketValue": "NA"
    },
    {
      "to": 487,
      "from": "Bayer",
      "partnership": "Investment",
      "sector": "Drug discovery and development",
      "modality": "Drug development in Women’s Healthcare",
      "companyName": "Daré Bioscience",
      "marketValue": 330
    },
    {
      "to": 488,
      "from": "Bayer",
      "partnership": "Acquisition",
      "sector": "Drug discovery and development",
      "modality": "Gene therapy",
      "companyName": "Viralgen Vector Core",
      "marketValue": 4000
    },
    {
      "to": 489,
      "from": "Bayer",
      "partnership": "Partnership",
      "sector": "Drug discovery and development",
      "modality": "Gene therapy",
      "companyName": "TAAV Biomanufacturing Solutions\n(Asklepios BioPharmaceutical and Touchlight)",
      "marketValue": "NA"
    },
    {
      "to": 490,
      "from": "Bayer",
      "partnership": "Acquisition",
      "sector": "Biotechnology",
      "modality": "AI-powered diagnostics",
      "companyName": "Blackford Analysis Inc",
      "marketValue": "NA"
    },
    {
      "to": 491,
      "from": "Bayer",
      "partnership": "Acquisition",
      "sector": "Drug discovery and development",
      "modality": "Gene therapy",
      "companyName": "Brain Neurotherapy Bio, Inc",
      "marketValue": "NA"
    },
    {
      "to": 492,
      "from": "Sanofi",
      "partnership": "Investment",
      "sector": "Biotechnology",
      "modality": "In-silico drug discovery",
      "companyName": "Aqemia",
      "marketValue": 140
    },
    {
      "to": 493,
      "from": "Sanofi",
      "partnership": "Investment",
      "sector": "Drug discovery and development",
      "modality": "RNA Therapeutics",
      "companyName": "MeiraGTx",
      "marketValue": 30
    },
    {
      "to": 494,
      "from": "Sanofi",
      "partnership": "Investment",
      "sector": "Drug discovery and development",
      "modality": "Precision Therapeutics ",
      "companyName": "QurAlis Corporation",
      "marketValue": 88
    },
    {
      "to": 495,
      "from": "Sanofi",
      "partnership": "Partnership",
      "sector": "Biotechnology",
      "modality": "In-silico drug discovery",
      "companyName": "Formation Bio (Formely TrialSpark )",
      "marketValue": "NA"
    },
    {
      "to": 496,
      "from": "Sanofi",
      "partnership": "Investment",
      "sector": "Drug discovery and development",
      "modality": "Precision Therapeutics ",
      "companyName": "Innate Pharma",
      "marketValue": 1456.4
    },
    {
      "to": 497,
      "from": "Sanofi",
      "partnership": "Investment",
      "sector": "Drug discovery and development",
      "modality": "Vaccines",
      "companyName": "Janssen Pharmaceuticals",
      "marketValue": 175
    },
    {
      "to": 498,
      "from": "Sanofi",
      "partnership": "Acquisition",
      "sector": "Drug discovery and development",
      "modality": "Cell therapy",
      "companyName": "Kiadis Pharma",
      "marketValue": 358
    },
    {
      "to": 499,
      "from": "Sanofi",
      "partnership": "Investment",
      "sector": "Drug discovery and development",
      "modality": "Gene editing technologies (CRISPR)",
      "companyName": "Scribe Therapeutics",
      "marketValue": 1025
    },
    {
      "to": 500,
      "from": "Sanofi",
      "partnership": "Acquisition",
      "sector": "Drug discovery and development ",
      "modality": "Precision Therapeutics ",
      "companyName": "Provention Bio",
      "marketValue": 2900
    },
    {
      "to": 501,
      "from": "Sanofi",
      "partnership": "Acquisition",
      "sector": "Drug manufacturing",
      "modality": "Protein and peptide-based Therapeutics",
      "companyName": "Kadmon Corporation",
      "marketValue": 1900
    },
    {
      "to": 502,
      "from": "Sanofi",
      "partnership": "Investment",
      "sector": "Biotechnology",
      "modality": "In-silico drug discovery",
      "companyName": "Exscientia",
      "marketValue": 5300
    },
    {
      "to": 503,
      "from": "Sanofi",
      "partnership": "Investment",
      "sector": "Biotechnology",
      "modality": "In-silico drug discovery",
      "companyName": "BioMap",
      "marketValue": 1010
    },
    {
      "to": 504,
      "from": "Sanofi",
      "partnership": "Acquisition",
      "sector": "Drug discovery and development",
      "modality": "Microbiome-based therapies",
      "companyName": "Origimm Biotechnology",
      "marketValue": "NA"
    },
    {
      "to": 505,
      "from": "Sanofi",
      "partnership": "Acquisition",
      "sector": "Biotechnology",
      "modality": "RNA Therapeutics",
      "companyName": "Tidal Therapeutics",
      "marketValue": 470
    },
    {
      "to": 506,
      "from": "Sanofi",
      "partnership": "Investment",
      "sector": "Drug Delivery Technology",
      "modality": "Precision Therapeutics ",
      "companyName": "Enable Injections",
      "marketValue": 50
    },
    {
      "to": 507,
      "from": "Sanofi",
      "partnership": "Acquisition",
      "sector": "Drug discovery and development",
      "modality": "Precision Therapeutics ",
      "companyName": "Kymab Limited",
      "marketValue": 1450
    },
    {
      "to": 508,
      "from": "Sanofi",
      "partnership": "Partnership",
      "sector": "Biotechnology",
      "modality": "In-silico drug discovery",
      "companyName": "NovAliX",
      "marketValue": "NA"
    },
    {
      "to": 509,
      "from": "Sanofi",
      "partnership": "Investment",
      "sector": "Drug discovery and development",
      "modality": "Protein and peptide-based Therapeutics",
      "companyName": "Teva Pharmaceuticals",
      "marketValue": 500
    },
    {
      "to": 510,
      "from": "Sanofi",
      "partnership": "Acquisition",
      "sector": "Biotechnology",
      "modality": "RNA Therapeutics",
      "companyName": "Translate Bio",
      "marketValue": 3200
    },
    {
      "to": 511,
      "from": "Sanofi",
      "partnership": "Investment",
      "sector": "Biotechnology",
      "modality": "Protein and peptide-based Therapeutics",
      "companyName": "Curadigm",
      "marketValue": "NA"
    },
    {
      "to": 512,
      "from": "Sanofi",
      "partnership": "Investment",
      "sector": "Healthcare SaaS",
      "modality": "Digital health tool",
      "companyName": "Click Therapeutics",
      "marketValue": 17
    },
    {
      "to": 513,
      "from": "Sanofi",
      "partnership": "Partnership",
      "sector": "Biotechnology",
      "modality": "In-silico drug discovery",
      "companyName": "BioMed X",
      "marketValue": "NA"
    },
    {
      "to": 514,
      "from": "Sanofi",
      "partnership": "Investment",
      "sector": "Biotechnology",
      "modality": "RNA Therapeutics",
      "companyName": "Massachusetts Institute of Technology (MIT)",
      "marketValue": 25
    },
    {
      "to": 515,
      "from": "Sanofi",
      "partnership": "Investment",
      "sector": "Drug discovery and development",
      "modality": "Precision Therapeutics ",
      "companyName": "Recludix Pharma",
      "marketValue": 1325
    },
    {
      "to": 516,
      "from": "Sanofi",
      "partnership": "Acquisition",
      "sector": "Drug discovery and development",
      "modality": "Protein and peptide-based Therapeutics",
      "companyName": "Inhibrx Inc",
      "marketValue": 1700
    },
    {
      "to": 517,
      "from": "Sanofi",
      "partnership": "Investment",
      "sector": "Drug discovery and development",
      "modality": "Small molecule therapy",
      "companyName": "Areteia Therapeutics",
      "marketValue": 350
    },
    {
      "to": 518,
      "from": "Sanofi",
      "partnership": "Acquisition",
      "sector": "Drug discovery and development",
      "modality": "Protein and peptide-based Therapeutics",
      "companyName": "Amunix Pharmaceuticals Inc",
      "marketValue": 1225
    },
    {
      "to": 519,
      "from": "Sanofi",
      "partnership": "Investment",
      "sector": "Biotechnology",
      "modality": "In-silico drug discovery",
      "companyName": "Owkin",
      "marketValue": 270
    },
    {
      "to": 520,
      "from": "Sanofi",
      "partnership": "Investment",
      "sector": "Drug discovery and development",
      "modality": "AI in clinical trials",
      "companyName": "Novadiscovery",
      "marketValue": 2.6
    },
    {
      "to": 521,
      "from": "Sanofi",
      "partnership": "Acquisition",
      "sector": "Drug discovery and development",
      "modality": "Small molecule therapy",
      "companyName": "Principia Biopharma",
      "marketValue": 3680
    },
    {
      "to": 522,
      "from": "Sanofi",
      "partnership": "Investment",
      "sector": "Biotechnology",
      "modality": "RNA Therapeutics",
      "companyName": "Translate Bio",
      "marketValue": 425
    },
    {
      "to": 523,
      "from": "Sanofi",
      "partnership": "Investment",
      "sector": "Drug discovery and development",
      "modality": "Precision Therapeutics ",
      "companyName": "Kymera Therapeutics Inc",
      "marketValue": 2150
    },
    {
      "to": 524,
      "from": "Sanofi",
      "partnership": "Acquisition",
      "sector": "Drug discovery and development",
      "modality": "Precision Therapeutics ",
      "companyName": "Synthorx, Inc.",
      "marketValue": 2500
    },
    {
      "to": 525,
      "from": "Sanofi",
      "partnership": "Investment",
      "sector": "Biotechnology",
      "modality": "In-silico drug discovery",
      "companyName": "Nurix Therapeutics",
      "marketValue": 2555
    },
    {
      "to": 526,
      "from": "Sanofi",
      "partnership": "Investment",
      "sector": "Drug discovery and development",
      "modality": "AI in clinical trials",
      "companyName": "Aetion",
      "marketValue": 27
    },
    {
      "to": 527,
      "from": "Sanofi",
      "partnership": "Investment",
      "sector": "Drug discovery and development",
      "modality": "Small molecule therapy",
      "companyName": "Denali Therapeutics",
      "marketValue": 1125
    },
    {
      "to": 528,
      "from": "Sanofi",
      "partnership": "Acquisition",
      "sector": "Drug discovery and development",
      "modality": "Protein and peptide-based Therapeutics",
      "companyName": "Ablynx",
      "marketValue": 4200
    },
    {
      "to": 529,
      "from": "Sanofi",
      "partnership": "Acquisition",
      "sector": "Drug discovery and development",
      "modality": "Protein and peptide-based Therapeutics",
      "companyName": "Bioverativ",
      "marketValue": 11600
    },
    {
      "to": 530,
      "from": "Sanofi",
      "partnership": "Partnership",
      "sector": "Drug Delivery Technology",
      "modality": "Ionic liquid technology",
      "companyName": "i2O Therapeutics",
      "marketValue": "NA"
    },
    {
      "to": 531,
      "from": "Sanofi",
      "partnership": "Investment",
      "sector": "Drug discovery and development",
      "modality": "Precision Therapeutics ",
      "companyName": "Sudo Biosciences",
      "marketValue": 116
    },
    {
      "to": 532,
      "from": "Sanofi",
      "partnership": "Investment",
      "sector": "Drug discovery and development",
      "modality": "Protein and peptide-based Therapeutics",
      "companyName": "IGM Biosciences",
      "marketValue": 6150
    },
    {
      "to": 533,
      "from": "Sanofi",
      "partnership": "Partnership",
      "sector": "Biotechnology",
      "modality": "Gene therapy",
      "companyName": "SIRION Biotech GmbH",
      "marketValue": "NA"
    },
    {
      "to": 534,
      "from": "Sanofi",
      "partnership": "Investment",
      "sector": "Drug discovery and development",
      "modality": "Protein and peptide-based therapeutics",
      "companyName": "Biond Biologics",
      "marketValue": 1125
    },
    {
      "to": 535,
      "from": "Sanofi",
      "partnership": "Investment",
      "sector": "Biotechnology",
      "modality": "In-silico drug discovery",
      "companyName": "Adagene",
      "marketValue": 2517.5
    },
    {
      "to": 536,
      "from": "Sanofi",
      "partnership": "Investment",
      "sector": "Drug discovery and development",
      "modality": "Bispecific antibodies",
      "companyName": "ABL Bio",
      "marketValue": 1060
    },
    {
      "to": 537,
      "from": "Sanofi",
      "partnership": "Investment",
      "sector": "Medical Devices & Equipment",
      "modality": "Therapeutic devices",
      "companyName": "BIOCORP",
      "marketValue": 8.07
    },
    {
      "to": 538,
      "from": "Sanofi",
      "partnership": "Partnership",
      "sector": "Healthcare SaaS",
      "modality": "Digital health tool",
      "companyName": "Health2Sync",
      "marketValue": "NA"
    },
    {
      "to": 539,
      "from": "Sanofi",
      "partnership": "Partnership",
      "sector": "Healthcare SaaS",
      "modality": "Digital health tool",
      "companyName": "BrightInsight Inc",
      "marketValue": "NA"
    }
  ]